Note: Descriptions are shown in the official language in which they were submitted.
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
DENDRIMER COMPOSITIONS AND METHODS FOR
DRUG DELIVERY TO THE EYE
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims benefit of U.S. Provisional Application No.
62/943,724, filed December 4, 2019, U.S. Provisional Application No.
63/021,023, filed May 6, 2020, and U.S. Provisional Application No.
63/108,234, filed October 30, 2020, which are incorporated by reference
herein in their entirety.
FIELD OF THE INVENTION
The invention is generally in the field of drug delivery, and in
particular, a method of delivering drugs selectively to activated immune cells
within the eye and surrounding tissue.
BACKGROUND OF THE INVENTION
The development of neuroinflammatory changes in the retina is a
significant factor in the pathogenesis of multiple retinal disorders including
glaucoma, diabetic retinopathy, and age-related macular degeneration.
Abnormal immune responses arising from physiological changes in
microglia, the primary resident innate immune cell in the retina, are thought
to drive aspects of disease progression, including neuronal degeneration and
pathological neovascularization (Karlstetter et al., 2015; Silverman and
Wong, 2018). Microglia are activated due to a complex interplay between
the different cell types of the retina and diverse pathological pathways.
Following activation, microglia cells lose their ramified protrusions,
proliferate and rapidly migrate to the damaged areas and resolve tissue
damage. However, sustained presence of tissue stress primes microglia to
become over-reactive and results in the excessive production of pro-
inflammatory mediators that favor retinal degenerative changes. A chronic
pro-inflammatory environment is a hallmark of retinal degenerative diseases
and neurological disorders that affect vision. Activation of retinal microglia
also occurs in a mouse model of ischemia/reperfusion injury (I/R), as occurs
in inflammatory diseases of the eye, including glaucoma, age related macular
1
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
degeneration (AMD), diabetic retinopathy and branch vein occlusion.
Retinal vascular occlusion, be it by high intra-ocular pressure in the I/R
model or thrombus in BYO, causes a decrease in blood flow within the eye,
resulting in retinal ischemia. This causes death of neurons initiating further
activation of microglia.
Enhanced production of pro-inflammatory and angiogenic factors
induces the formation and growth of new blood vessels from the choroid into
the subretinal space, mimicking features of exudative AMD in a laser-
induced CNV mouse model (Lambert V, et al., Nat. Protoc. 8, 2197-2211
(2013)). Several circumstances, such as ischemia, hypoxia or inflammation,
can promote neovascularization. Pathological ocular angiogenesis,
particularly in the retina and choroid, can lead to significant visual
impairment. Diabetic retinopathy, neovascular age-related macular
degeneration (AMD), retinopathy of prematurity, and retinal vessel occlusion
are major causes of angiogenesis-related vision loss.
Exudative (wet form) AMD is characterized by serous or
hemorrhagic separation of the retinal pigment epithelium or neurosensory
layer. Patients may develop choroidal neovascularization (CNV), which is
manifested as fluid accumulation, hemorrhage, and/or lipid exudation. The
earliest stage of diabetic retinopathy (DR) is characterized by retinal
vascular
abnormalities including microaneurysms (saccular out-pouchings from the
capillary wall), intraretinal hemorrhages, and cotton-wool spots (nerve fiber
layer infarctions). As the disease progresses, the gradual closure of retinal
vessels results in retinal ischemia, giving rise to signs including venous
abnormalities (beading, loops), intraretinal microvascular abnormalities, and
increasing retinal hemorrhage and exudation. Non-proliferative DR is
graded as mild, moderate, severe, and very severe according to the presence
and extent of the above lesions. The more advanced stage of DR involves the
formation of new blood vessels, induced by the retinal ischemia, which
spreads out either from the disc (neovascularization of the disc, NVD) or
from elsewhere in the retina (neovascularization elsewhere, NVE). New
vessels extending into the vitreous can cause vitreous hemorrhage, and
2
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
tractional retinal detachments associated with accompanying contractile
fibrous tissue.
To date, the only treatment conclusively demonstrated to be of long-
term benefit for DR is focal laser photocoagulation. The standard treatment
for patients with AMD is intravitreal injections of anti-VEGF into the eye to
slow disease progression, and there have been studies that have shown that
anti-VEGF therapy may be useful in diabetic macular edema (DME).
However, there are at present no systemic treatments available for ischemic
retinopathies or AMD. These would involve less frequent injections due to
retention in microglia and ability to delivery systemically, avoiding frequent
intraocular injections as in current anti-VEGF therapies.
Therefore, it is an object of the invention to provide compositions and
methods for effective therapies for one or more inflammatory and/or
angiogenic diseases of the eye, particularly DME, DR and AMD.
It is another object of the invention to provide compositions and
methods for targeted delivery of one or more active agents to the diseased
tissues/cells in the eye via systemic administration with increased efficacy
and reduced side effects.
It is a further object to provide compositions and methods for
targeted delivery of one or more active agents to activated microglia
associated with one or more inflammatory and/or angiogenic diseases of the
eye.
It is also an object to provide compositions and methods effective for
inhibiting or reducing pro-inflammatory and/or angiogenic factors associated
with one or more inflammatory and/or angiogenic diseases of the eye.
SUMMARY OF THE INVENTION
Compositions and methods for selective delivery of one or more
therapeutic, prophylactic and/or diagnostic agents to treat and/or diagnose
one or more diseases and/or disorders of the eye have been developed. The
compositions deliver one or more therapeutic, prophylactic and/or diagnostic
agents selectively to activated microglial cells to treat and/or diagnose
diseases tissues/cells of the eye.
3
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Compositions include hydroxyl-terminated dendrimer complexed,
covalently conjugated or intra-molecularly dispersed or encapsulated with
one or more receptor tyrosine kinase inhibitors in an amount effective to
reduce the number or activity of the activated microglia and macrophages in
the retina and/or the choroid in a subject in need thereof. In some
embodiments, the receptor tyrosine kinase inhibitor is an inhibitor of
vascular endothelial growth factor receptors such as sunitinib, sorafenib,
pazopanib, vandetanib, axitinib, cediranib, vatalanib, dasatinib, nintedanib,
motesanib, and analogues thereof. Preferably, the receptor tyrosine kinase
inhibitor is sunitinib or an analogue thereof. In some embodiments, the
diagnostic agents are dyes, such as fluorescent dyes, Near infra-red dyes,
SPECT imaging agents, PET imaging agents and radioisotopes. Preferably,
the diagnostic agent is the fluorescent dye indocyanine green (ICG).
In some embodiments, the dendrimer is a generation 4, generation 5,
generation 6, generation 7, generation 8, generation 9, or generation 10
PAMAM dendrimer. In some embodiments, the one or more therapeutic,
prophylactic and/or diagnostic agents are covalently conjugated to the
dendrimers.
In some embodiments, the one or more therapeutic, prophylactic
and/or diagnostic agents are at a concentration by weight of agent to
dendrimer conjugate of between about 0.01% weight to weight (w/w) to
about 30% w/w, about 1% w/w to about 25% w/w, about 5% w/w to about
20% w/w, and about 10% w/w to about 15% w/w.
In some embodiments, one or more spacers or linkers between a
dendrimer and an agent are added to provide a releasable (or cleavable) or
non-releasable (or non-cleavable) form of the dendrimer-agent complexes in
vivo. In some embodiments, the attachment occurs via an appropriate spacer
that provides an ester bond between the agent and the dendrimer. In some
embodiments, the attachment occurs via an appropriate spacer that provides
an ether bond between the agent and the dendrimer. In some embodiments,
the attachment occurs via an appropriate spacer that provides an amide bond
between the agent and the dendrimer. In preferred embodiments, one or more
4
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
spacers/linkers between a dendrimer and an agent are tailored to achieve
desired and effective release kinetics in vivo.
The compositions are suitable for treating and/or diagnosing one or
more inflammatory and/or angiogenic diseases of the eye, for example, age-
related macular degeneration (AMD), retinitis pigmentosa, optic neuritis,
uveitis, retinal detachment, temporal arteritis, retinal ischemia,
arteriosclerotic retinopathy, hypertensive retinopathy, retinal artery
blockage,
retinal vein blockage, diabetic retinopathy, macular edema, retinal
neovascularization, and choroidal neovascularization.
Methods of making the dendrimer compositions are provided.
Dosage forms and pharmaceutical formulations including an effective
amount of the dendrimer compositions for administration to a subject in need
thereof are also provided.
Methods of treating and/or diagnosing one or more diseases and/or
disorders of the eye by administering to a subject in need thereof an
effective
amount of the compositions are described. The methods are effective in
treating and/or diagnosing one or more diseases and/or disorders of the eye,
including age-related macular degeneration (AMD), retinitis pigmentosa,
optic neuritis, uveitis, retinal detachment, temporal arteritis, retinal
ischemia,
arteriosclerotic retinopathy, hypertensive retinopathy, retinal artery
blockage,
retinal vein blockage, diabetic retinopathy, macular edema, retinal
neovascularization, and choroidal neovascularization. In particular, the
methods are effective for treating and/or diagnosing one or more diseases
and/or disorders of the eye associated with activated microglia within the eye
and surrounding tissue. Typically, the compositions are administered in an
amount effective to target the activated microglia, retinal pigment epithelia
(RPE) cells, and/or choroidal neovascular (CNV) lesions, and/or to alleviate
one or more symptoms of the one or more one or more diseases and/or
disorders of the eye.
Methods of administering the compositions and pharmaceutical
formulations are also provided. Typically, the compositions and
pharmaceutical formulations are administered via one or more systemic
5
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
routes daily, weekly, biweekly, monthly, bimonthly, or less frequently. In
some embodiments, the compositions and pharmaceutical formulations are
administered via one or more systemic routes once every four weeks or less
frequently. In preferred embodiments, the compositions and pharmaceutical
formulations are administered via the intravenous, subcutaneous, or oral
route.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1A and 1B are schemes showing chemical reaction steps for
the synthesis of a dendrimer-sunitinib conjugate. Sunitinib is conjugated to
the dendrimer via a hydroxymethyl linkage (FIG.1A), and an amide linkage
(FIG.1B), respectively.
Figures 2A and 2B are bar graphs showing levels of isolectin
(FIG.2A), and IBA-1 (FIG.2B), showing signal area (p,m2) for each of 4
hours (4h) and 24 hours (24h), at day 1, 3, 7 and 14 post-laser, respectively,
as analyzed by optical coherence tomography with ICG imaging at 4 or 24 hr
post-dose with D-ICG. Figure 2C is a bar graph showing corrected total
lesion fluorescence over a period of 28 days after a single systemic
dendrimer-indocyanine green (D-ICG) dose given 24 hr after laser injury
localized to the choroidal neovascularization (CNV) lesion in C57BL/6 mice.
Figure 3 is a bar graph showing mean area of choroidal
neovascularization (CNV) (mm2) in the eyes of mice treated with vehicle,
aflibercept, a cleavable sunitinib analog (D-CSA) at a low dose (D-CSA low)
or a high dose (D-CSA high), a non-cleavable sunitinib analog (D-NSA) at a
low dose (D-NSA low) or a high dose (D-NSA high), and free sunitinib
administered 24 hr after laser-induced rupture of Bruch's membrane in the
eyes of C57BL/6 mice (n=8/group for all except D-NSA High where n=6). P
values are indicated as compared to the vehicle control.
Figure 4A is a bar graph showing mean area of choroidal
neovascularization (CNV) (mm2) in the eyes of mice treated with free
sunitinib, a cleavable sunitinib analog (D-CSA), a non-cleavable sunitinib
analog (D-NSA), and aflibercept administered 24 hr after laser-induced
rupture of Bruch's membrane in the eyes of C57BL/6 mice (n=8/group) at
6
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
day 7 and day 14 post-treatment, respectively. Figure 4B is a line plot
showing plasma concentration ( g/m1) of dendrimer sunitinib analog
conjugates over time for a period of 0-72 hours.
Figure 5 is a reaction scheme showing one synthesis strategy of N, N-
S didesethyl sunitinib azide with an amide linkage.
Figures 6A and 6B are schemes showing chemical reaction steps for
the synthesis of an exemplary dendrimer-sunitinib conjugate via first
synthesizing dendrimer-hexynoic-acid conjugate (FIG.6A), prior to the step
of synthesizing dendrimer-didesethyl-sunitinib amide-conjugate (FIG.6B).
G4 PAMAM dendrimer is used as an exemplary dendrimer.
Figure 7 is a line graph showing in vitro release profile (loss of linker
with AVT-4517 %w/w) of D-didesethyl sunitinib conjugate (D-4517) pH 7.4
and pH 5.5 over a period of 15 days with esterases at 37 C mimicking
plasma and intracellular conditions respectively.
Figure 8 is a line graph showing plasma concentration in lig/mL over
time in Female C57/B16 mice injected IP with 5 or 50 mg/kg D-4517.
Figures 9A and 9B are line graphs showing plasma concentration in
lig/mL over time (0-24 hours) for male and female groups of Sprague-
Dawley rats that received daily IP injections of 12 mg/kg D-4517 and daily
oral dose of 30 mg/kg sunitinib (40.21 mg/kg of sunitinib malate) on Day 1
(FIG.9A), and Day 14 (FIG.9B), respectively.
Figure 10 is a bar graph showing mean area of choroidal
neovascularization (CNV) ( m2) in the eyes of mice treated with vehicle,
aflibercept (40 pg), and three dose levels of D-didesethyl sunitinib conjugate
(D-4517) at 2, 10 and 50 mg/kg in a single subcutaneous dose administered
24 hr after laser-induced rupture of Bruch's membrane in the eyes of
C57BL/6 mice at day 14 post-treatment.
Figure 11 is a scheme showing the synthesis of an exemplary
dendrimer- conjugate (D-4517.2) in which N, N-didesethyl sunitinib is
conjugated to a dendrimer with ether linkages for enhanced in vivo stability.
Figure 12 is a schematic showing the chemical structure of compound
D-4517.2.
7
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Figure 13 is a bar graph showing drug release percentage by weight
(0.0%-0.50%) of D-didesethyl sunitinib conjugate, D-4517.2, in human,
mouse, and rat plasma conditions over time points for each of 4, 24 and 48
hours, respectively.
Figure 14 is a synthesis scheme for Dendrimer-N-Acetyl-L-cysteine
methyl ester conjugate (Dendrimer-NAC-carboxymethylated conjugate).
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
The terms "active agent" or "biologically active agent" are
therapeutic, prophylactic or diagnostic agents used interchangeably to refer
to a chemical or biological compound that induces a desired pharmacological
and/or physiological effect, which may be prophylactic, therapeutic or
diagnostic. These may be a nucleic acid, a nucleic acid analog, a small
molecule having a molecular weight less than 2 kDa, more typically less than
1 kDa, a peptidomimetic, a protein or peptide, carbohydrate or sugar, lipid,
or surfactant, or a combination thereof. The terms also encompass
pharmaceutically acceptable, pharmacologically active derivatives of active
agents, including, but not limited to, salts, esters, amides, prodrugs, active
metabolites, and analogs.
The term "pharmaceutically acceptable salts" is art-recognized, and
includes relatively non-toxic, inorganic and organic acid addition salts of
compounds. Examples of pharmaceutically acceptable salts include those
derived from mineral acids, such as hydrochloric acid and sulfuric acid, and
those derived from organic acids, such as ethanesulfonic acid,
benzenesulfonic acid, and p-toluenesulfonic acid. Examples of suitable
inorganic bases for the formation of salts include the hydroxides, carbonates,
and bicarbonates of ammonia, sodium, lithium, potassium, calcium,
magnesium, aluminum, and zinc. Salts may also be formed with suitable
organic bases, including those that are non-toxic and strong enough to form
such salts. For purposes of illustration, the class of such organic bases may
include mono-, di-, and trialkylamines, such as methylamine, dimethylamine,
and triethylamine; mono-, di- or trihydroxyalkylamines such as mono-, di-,
8
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
and triethanolamine; amino acids, such as arginine and lysine; guanidine; N-
methylglucos amine; N-methylglucamine; L-glutamine; N-methylpiperazine;
morpholine; ethylenediamine; N-benzylphenethylamine;
The term "therapeutic agent" refers to an active agent that can be
administered to treat one or more symptoms of a disease or disorder.
The term "diagnostic agent" refers to an active agent that can be
administered to reveal, pinpoint, and define the localization of a
pathological
process. The diagnostic agents can label target cells that allow subsequent
detection or imaging of these labeled target cells. In some embodiments,
diagnostic agents can, via dendrimer or suitable delivery vehicles,
target/bind
activated microglia, activated macrophages, and/or RPE cells.
The term "prophylactic agent" refers to an active agent that can be
administered to prevent disease or to prevent certain conditions.
The phrase "pharmaceutically acceptable", or "biocompatible" refers
to compositions, polymers and other materials and/or dosage forms which
are, within the scope of sound medical judgment, suitable for use in contact
with the tissues of human beings and animals without excessive toxicity,
irritation, allergic response, or other problem or complication, commensurate
with a reasonable benefit/risk ratio. The phrase "pharmaceutically acceptable
carrier" refers to pharmaceutically acceptable materials, compositions or
vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating
material involved in carrying or transporting any subject composition, from
one organ, or portion of the body, to another organ, or portion of the body.
Each carrier must be "acceptable" in the sense of being compatible with the
other ingredients of a subject composition and not injurious to the patient.
The term "therapeutically effective amount" refers to an amount of
the therapeutic agent that, when incorporated into and/or onto dendrimers,
produces some desired effect at a reasonable benefit/risk ratio applicable to
any medical treatment. The effective amount may vary depending on such
factors as the disease or condition being treated, the particular targeted
constructs being administered, the size of the subject, or the severity of the
disease or condition. One of ordinary skill in the art may empirically
9
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
determine the effective amount of a particular compound without
necessitating undue experimentation. In some embodiments, the term
"effective amount" refers to an amount of a therapeutic agent or prophylactic
agent to reduce or diminish the symptoms of one or more eye diseases or
disorders, such as reducing inflammation by reducing or inhibiting one or
more pro-inflammatory cytokines and/cells associated with the diseased
tissues/cells in the eye. In the case of retinal and/or choroidal
neovascularization, an effective amount of the drug may have the effect in
reducing retinal and/or choroidal angiogenesis; inhibiting to some extent
vascular endothelial cell growth/proliferation; and/or relieving to some
extent one or more of the symptoms associated with the disorder. An
effective amount can be administered in one or more administrations.
The terms "inhibit" or "reduce" in the context of inhibition, mean to
reduce or decrease in activity and quantity. This can be a complete inhibition
or reduction in activity or quantity, or a partial inhibition or reduction.
Inhibition or reduction can be compared to a control or to a standard level.
Inhibition can be 5, 10, 25, 50, 75, 80, 85, 90, 95, 99, or 100%. For example,
dendrimer compositions including one or more therapeutic agents may
inhibit or reduce the activity and/or quantity of activated microglia and
macrophages in the diseased retina and/or choroid of a subject by about 10%,
20%, 30%, 40%, 50%, 75%, 85%, 90%, 95%, or 99% from the activity
and/or quantity of the same cells in equivalent diseased tissues of subjects
that did not receive, or were not treated with the dendrimer compositions
(i.e., un-conjugated active agents). In some embodiments, the inhibition and
reduction are compared at mRNAs, proteins, cells, tissues and organs levels.
For example, an inhibition and/or reduction in pro-inflammatory cytokines
(e.g., TNF-a, interleukin-113 (IL-1 13), or interferon-y (IFN-y)) secreted by
the
activated microglia and macrophages in the diseased retina and/or choroid.
The term "treating" or "preventing" a disease, disorder or condition
from occurring in an animal which may be predisposed to the disease,
disorder and/or condition but has not yet been diagnosed as having it;
inhibiting the disease, disorder or condition, e.g., impeding its progress;
and
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
relieving the disease, disorder, or condition, e. g. , causing regression of
the
disease, disorder and/or condition. Treating the disease or condition includes
ameliorating at least one symptom of the particular disease or condition,
even if the underlying pathophysiology is not affected, such as treating the
pain of a subject by administration of an analgesic agent even though such
agent does not treat the cause of the pain. Desirable effects of treatment
include decreasing the rate of disease progression, ameliorating or palliating
the disease state, and remission or improved prognosis. For example, an
individual is successfully "treated" if one or more symptoms associated with
an eye disease or disorder are mitigated or eliminated, including, but are not
limited to, reducing the proliferation of pro-inflammatory cells, decreasing
symptoms resulting from the disease, enhancing or restoring vision,
decreasing the extent and rate of vision loss, increasing the quality of life
of
those suffering from the disease, decreasing the dose of other medications
required to treat the disease, delaying the progression of the disease, and/or
prolonging survival of individuals.
The term "biodegradable" refers to a material that will degrade or
erode under physiologic conditions to smaller units or chemical species that
are capable of being metabolized, eliminated, or excreted by the subject.
The degradation time is a function of composition and morphology.
The term "dendrimer" includes, but is not limited to, a molecular
architecture with an interior core, interior layers (or "generations") of
repeating units regularly attached to this initiator core, and an exterior
surface of terminal groups attached to the outermost generation.
The term "functionalize" means to modify a compound or molecule
in a manner that results in the attachment of a functional group or moiety.
For example, a molecule may be functionalized by the introduction of a
molecule which makes the molecule a strong nucleophile or strong
electrophile.
The term "targeting moiety" refers to a moiety that localizes to or
away from a specific locale. The moiety may be, for example, a protein,
nucleic acid, nucleic acid analog, carbohydrate, or small molecule. The entity
11
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
may be, for example, a therapeutic compound such as a small molecule, or a
diagnostic entity such as a detectable label. The locale may be a tissue, a
particular cell type or cell activation state, or a subcellular compartment.
In
some embodiments, the targeting moiety directs the localization of an active
agent.
The term "prolonged residence time" refers to an increase in the time
required for an agent to be cleared from a patient's body, or organ or tissue
of
that patient. In certain embodiments, "prolonged residence time refers to an
agent that is cleared with a half-life that is 10%, 20%, 50% or 75% longer
than a standard of comparison such as a comparable agent without
conjugation to a delivery vehicle such as a dendrimer. In certain
embodiments, "prolonged residence time refers to an agent that is cleared
with a half-life of 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, or
10000
times longer than a standard of comparison such as a comparable agent
without a dendrimer that specifically target specific cell types associated
with tumors.
The terms "incorporated" and "encapsulated" refer to incorporating,
formulating, or otherwise including an active agent into and/or onto a
composition that allows for release, such as sustained release, of such agent
in the desired application. The active agent or other material can be
incorporated into a dendrimer, including to one or more surface functional
groups of such dendrimer (by covalent, ionic, or other binding interaction),
physical admixture, enveloping the agent within the dendritic structure,
encapsulated inside the dendritic structure, etc.
II. Compositions
Dendrimer complexes suitable for delivering one or more active
agent, particularly one or more active agents to prevent, treat or diagnose
one
or more diseases or disorders of the eye.
Compositions of dendrimer complexes include one or more
prophylactic, therapeutic, and/or diagnostic agents encapsulated, associated,
and/or conjugated in the dendrimer complex at a concentration by weight of
about 0.01% weight to weight (w/w) to about 30% w/w, about 1% w/w to
12
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
about 25% w/w, about 5% w/w to about 20% w/w, and about 10% w/w to
about 15% w/w. In some embodiments, prophylactic, therapeutic, and/or
diagnostic agents are covalently conjugated to the dendrimer via one or more
linkages selected from disulfide, ester, ether, thioester, carbamate,
carbonate,
hydrazine, and amide, optionally via one or more spacers. Preferably,
hydroxyl groups of hydroxyl-terminated dendrimers are covalently
conjugated to one or more active agents via at least one ether linkage,
optionally via one or more linkers/spacers. In preferred embodiments,
surface groups of hydroxyl-terminated dendrimers are modified via
etherification reaction prior to conjugation to one or more linkers and the
active agent. Where one or more linkers are present between dendrimers and
active agents, the covalent bond between the surface groups of dendrimers
and the linkers are ether bonds. In other embodiments, at dendrimer
generation 3.5, alkyne functional groups are introduced using a polyethyl
glycol (PEG) linker with an amine at one end and a hexyne at the other end
to produce a generation 4 bifunctional dendrimer. An exemplary bifunctional
dendrimer is shown as compound 1 in FIG. 11 with 7 alkyne arms and 57
hydroxyl groups on the surface.
In some embodiments, the spacer is a prophylactic, therapeutic,
and/or diagnostic agent, such as sunitinib. Exemplary active agents include
antiangiogenic agents, anti-inflammatory drugs, and anti-infective agents.
The presence of the additional agents can affect the zeta-potential, or
the surface charge of the particle. In one embodiment, the zeta potential of
the dendrimers is -100 mV and 100 mV, between -50 mV and 50 mV,
between -25 mV and 25 mV, between -20 mV and 20 mV, between -10 mV
and 10 mV, between -10 mV and 5 mV, between -5 mV and 5 mV, or
between -2 mV and 2 mV. In a preferred embodiment, the surface charge is
neutral or near-neutral. The range above is inclusive of all values from -100
mV to 100 mV.
13
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
A. Dendrimers
Dendrimers are three-dimensional, hyperbranched, monodispersed,
globular and polyvalent macromolecules having a high density of surface
end groups (Tomalia, D. A., et al., Biochemical Society Transactions, 35, 61
(2007); and Sharma, A., et al., ACS Macro Letters, 3, 1079 (2014)). Due to
their unique structural and physical features, dendrimers are useful as nano-
carriers for various biomedical applications including targeted drug/gene
delivery, imaging and diagnosis (Sharma, A., et al., RSC Advances, 4, 19242
(2014); Caminade, A.-M., et al., Journal of Materials Chemistry B, 2, 4055
(2014); Esfand, R., et al., Drug Discovery Today, 6, 427 (2001); and
Kannan, R. M., et al., Journal of Internal Medicine, 276, 579 (2014)).
Dendrimer surface groups have a significant impact on their
biodistribution (Nance, E., et al., Biomaterials, 101, 96 (2016)). Hydroxyl
terminated generation 4 PAMAM dendrimers (-4 nm size) without any
targeting ligand cross the impaired BBB upon systemic administration in a
rabbit model of cerebral palsy (CP) significantly more (> 20 fold) as
compared to healthy controls, and selectively target activated microglia and
astrocytes (Lesniak, W. G., et al., Mol Pharm, 10 (2013)).
The term "dendrimer" includes a molecular architecture with an
interior core and layers (or "generations") of repeating units which are
attached to and extend from this interior core, each layer having one or more
branching points, and an exterior surface of terminal groups attached to the
outermost generation. In some embodiments, dendrimers have regular
dendrimeric or "starburst" molecular structures.
Generally, dendrimers have a diameter from about 1 nm up to about
50 nm, more preferably from about 1 nm to about 20 nm, from about 1 nm to
about 10 nm, or from about 1 nm to about 5 nm. In some embodiments, the
diameter is between about 1 nm to about 2 nm. Conjugates are generally in
the same size range, although large proteins such as antibodies may increase
the size by 5-15 nm. In general, agent is encapsulated in a ratio of agent to
dendrimer of between 1:1 to 4:1 for the larger generation dendrimers. In
preferred embodiments, the dendrimers have a diameter effective to
14
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
penetrate ocular tissue and to be retained in target cells for a prolonged
period of time.
In some embodiments, dendrimers have a molecular weight between
about 500 Daltons to about 100,000 Daltons, preferably between about 500
Daltons to about 50,000 Daltons, most preferably between about 1,000
Daltons to about 20,000 Dalton.
Suitable dendrimers scaffolds that can be used include
poly(amidoamine), also known as PAMAM, or STARBURSTTm dendrimers;
polypropylamine (POPAM), polyethylenimine, polylysine, polyester,
iptycene, aliphatic poly(ether), and/or aromatic polyether dendrimers. The
dendrimers can have carboxylic, amine and/or hydroxyl terminations. In
preferred embodiments, the dendrimers have hydroxyl terminations. Each
dendrimer of the dendrimer complex may be same or of similar or different
chemical nature than the other dendrimers (e.g., the first dendrimer may
include a PAMAM dendrimer, while the second dendrimer may be a
POPAM dendrimer).
The term "PAMAM dendrimer" means poly(amidoamine) dendrimer,
which may contain different cores, with amidoamine building blocks, and
can have carboxylic, amine and hydroxyl terminations of any generation
including, but not limited to, generation 1 PAMAM dendrimers, generation 2
PAMAM dendrimers, generation 3 PAMAM dendrimers, generation 4
PAMAM dendrimers, generation 5 PAMAM dendrimers, generation 6
PAMAM dendrimers, generation 7 PAMAM dendrimers, generation 8
PAMAM dendrimers, generation 9 PAMAM dendrimers, or generation 10
PAMAM dendrimers. In the preferred embodiment, the dendrimers are
soluble in the formulation and are generation ("G") 4, 5 or 6 dendrimers. In
preferred embodiments, dendrimers have a plurality of hydroxyl groups
attached to their functional surface groups.
Methods for making dendrimers are known to those of skill in the art
and generally involves a two-step iterative reaction sequence that produces
concentric shells (generations) of dendritic 0-alanine units around a central
initiator core (e.g., ethylenediamine-cores). Each subsequent growth step
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
represents a new "generation" of polymer with a larger molecular diameter,
twice the number of reactive surface sites, and approximately double the
molecular weight of the preceding generation. Dendrimer scaffolds suitable
for use are commercially available in a variety of generations. Preferable,
the
dendrimeric compounds are based on generation 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or
dendrimeric scaffolds. Such scaffolds have, respectively, 4, 8, 16, 32, 64,
128, 256, 512, 1024, 2048, and 4096 reactive sites. Thus, the dendrimeric
compounds based on these scaffolds have the corresponding number of
combined targeting moieties and modulators.
10 In some embodiments, the dendrimers include a plurality of hydroxyl
groups. Some exemplary high-density hydroxyl groups-containing
dendrimers include commercially available polyester dendritic polymer such
as hyperbranched 2,2-Bis(hydroxyl-methyl)propionic acid polyester polymer
(for example, hyperbranched bis-MPA polyester-64-hydroxyl, generation 4),
dendritic polyglycerols.
In some embodiments, the high-density hydroxyl groups-containing
dendrimers are oligo ethylene glycol (0EG)-like dendrimers. For example, a
generation 2 OEG dendrimer (D2-0H-60) can be synthesized using highly
efficient, robust and atom economical chemical reactions such as Cu (I)
catalyzed alkyne¨azide click and photo catalyzed thiol-ene click chemistry.
Highly dense polyol dendrimer at very low generation in minimum reaction
steps can be achieved by using an orthogonal hypermonomer and hypercore
strategy, for example as described in WO 2019094952. In some
embodiments, dendrimer backbone has non-cleavable polyether bonds
throughout the structure to avoid the disintegration of dendrimer in vivo, and
to allow the elimination of such dendrimers as a single entity from the body
(non-biodegradable).
In some embodiments, the dendrimer is able to specifically target a
particular tissue region and/or cell type, preferably activated microglia and
macrophages associated with one or more eye diseases. In preferred
embodiments, the dendrimer is able to specifically target a particular tissue
region and/or cell type without addition of a targeting moiety.
16
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
In preferred embodiments, the dendrimers have a plurality of
hydroxyl (-OH) groups on the surface of the dendrimers. The preferred
surface density of hydroxyl (-OH) groups is at least 1 OH group/nm2
(number of hydroxyl surface groups/surface area in nm2). For example, in
some embodiments, the surface density of hydroxyl groups is more than 2, 3,
4, 5, 6, 7, 8, 9, 10; preferably at least 10, 15, 20, 25, 30, 35, 40, 45, 50,
or
more than 50 surface groups/surface area in nm2. In further embodiments,
the surface density of hydroxyl (-OH) groups is between about 1 and about
50, preferably 5-20 OH group/nm2 (number of hydroxyl surface
groups/surface area in nm2) while having a molecular weight of between
about 500 Da and about 10 I(Da. In preferred embodiments, the percentage of
free, i.e., un-conjugated hydroxyl groups out of total surface groups
(conjugated and un-conjugated) on the dendrimer is more than 70%, 75%,
80%, 85%, 90%, 95%, and/or less than 100%. In the case of generation 4
PAMAM dendrimers, the preferred number of free, i.e., un-conjugated
hydroxyl groups is more than 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61,
62, or 63 out of total 64 surface terminals/groups. In further embodiments,
the hydroxyl terminated dendrimers have an effective number of free
hydroxyl groups for selective targeting to activated microglia, activated
microphages, and/or RPE cells associated with one or more diseases and/or
disorders of the eye.
In some embodiments, the dendrimers may have a fraction of the
hydroxyl groups exposed on the outer surface, with the others in the interior
core of the dendrimers. In preferred embodiments, the dendrimers have a
volumetric density of hydroxyl (-OH) groups of at least 1 OH group/nm3
(number of hydroxyl groups/volume in nm3). For example, in some
embodiments, the volumetric density of hydroxyl groups is 2, 3, 4, 5, 6, 7, 8,
9, 10, or more than 10, 15, 20, 25, 30, 35, 40, 45, and 50 hydroxyl
groups/volume in nm3. In some embodiments, the volumetric density of
hydroxyl groups is between about 4 to about 50 hydroxyl groups/nm3,
preferably between about 5 to about 30 hydroxyl groups/nm3, more
preferably between about 10 to about 20 hydroxyl groups/nm3.
17
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
B. Coupling Agents and Spacers
Dendrimer complexes can be formed of therapeutically active agents
or compounds conjugated or attached to a dendrimer, a dendritic polymer or
a hyperbranched polymer. Optionally, the active agents are conjugated to
the dendrimers via one or more spacers/linkers via different linkages such as
disulfide, ester, carbonate, carbamate, thioester, hydrazine, hydrazides, and
amide linkages. The one or more spacers/linkers between a dendrimer and an
agent can be designed to provide a releasable (or cleavable) or non-
releasable (or non-cleavable) form of the dendrimer-active complexes in
vivo. In some embodiments, the attachment occurs via an appropriate spacer
that provides an ester bond between the agent and the dendrimer. In some
embodiments, the attachment occurs via an appropriate spacer that provides
an amide bond between the agent and the dendrimer. In preferred
embodiments, one or more spacers/linkers between a dendrimer and an agent
are added to achieve a desired and effective release kinetics in vivo. In
further embodiments, the conjugation of dendrimer and/or linker does not
significantly affect the activities of the active agents. For example, in the
case of VEGFR TKR inhibitors, they retain their binding affinity towards
one or more of VEGFR TKR after conjugation to dendrimers at a level
comparable to unconjugated VEGFR TKR inhibitors.
The term "spacer" includes moieties and compositions used for
linking a therapeutically active agent to the dendrimer. The spacer can be
either a single chemical entity or two or more chemical entities linked
together to bridge the dendrimer and the active agent. The spacers can
include any small chemical entity, peptide or polymers having sulfhydryl,
thiopyridine, succinimidyl, maleimide, vinylsulfone, and carbonate
terminations.
The spacer can be chosen from among a class of compounds
terminating in sulfhydryl, thiopyridine, succinimidyl, maleimide,
vinylsulfone and carbonate group. The spacer can include thiopyridine
terminated compounds such as dithiodipyridine, N-Succinimidyl 3-(2-
pyridyldithio)-propionate (SPDP), Succinimidyl
18
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
propionamido)hexanoate LC-SPDP or Sulfo-LC-SPDP. The spacer can also
include peptides wherein the peptides are linear or cyclic essentially having
sulfhydryl groups such as glutathione, homocysteine, cysteine and its
derivatives, arg-gly-asp-cys (RGDC), cyclo(Arg-Gly-Asp-d-Phe-Cys)
(c(RGDfC)), cyclo(Arg-Gly-Asp-D-Tyr-Cys), and cyclo(Arg-Ala-Asp-d-
Tyr-Cys). In some embodiments, the spacer includes a mercapto acid
derivative such as 3 mercapto propionic acid, mercapto acetic acid, 4
mercapto butyric acid, thiolan-2-one, 6 mercaptohexanoic acid, 5 mercapto
valeric acid and other mercapto derivatives such as 2 mercaptoethanol and 2
mercaptoethylamine. In some embodiments, the spacer includes thiosalicylic
acid and its derivatives, (4-succinimidyloxycarbonyl-methyl-alpha-2-
pyridylthio)toluene, (342-pyridithiolpropionyl hydrazide. In some
embodiments, the spacer includes maleimide terminations wherein the spacer
includes polymer or small chemical entity such as bis-maleimido diethylene
glycol and bis-maleimido triethylene glycol, Bis-Maleimidoethane, and
bismaleimidohexane. In some embodiments, the spacer includes vinylsulfone
such as 1,6-Hexane-bis-vinylsulfone. In some embodiments, the spacer
includes thioglycosides such as thioglucose. In other embodiments, the
spacer includes reduced proteins such as bovine serum albumin and human
serum albumin, any thiol terminated compound capable of forming disulfide
bonds. In particular embodiments, the spacer includes polyethylene glycol
having maleimide, succinimidyl and thiol terminations.
The therapeutically active agent, imaging agent, and/or targeting
moiety can be either covalently attached or intra-molecularly dispersed or
encapsulated. The dendrimer is preferably a PAMAM dendrimer of
generation 1 (G1), G2, G3, G4, G5, G6, G7, G8, G9 or G10, having
carboxylic, hydroxyl, or amine terminations. In preferred embodiments, the
dendrimer is linked to active agents via a spacer ending in ether or amide
bonds.
In some embodiments, a non-releasable form of the dendrimer/active
agent complex provides enhanced therapeutic efficacy as compared to a
releasable or cleavable form of the same dendrimer/active agent complex.
19
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Therefore, in some embodiments, one or more active agent(s) is conjugated
to the dendrimer via a spacer that is attached to the dendrimer in a non-
releasable manner, for example, by an ether or amide bond. In some
embodiments, one or more active agent(s) is attached to the spacer in a non-
releasable manner, for example, by an ether or amide bond. Therefore, in
some embodiments, one or more active agent(s) is attached to the dendrimer
via a spacer that is attached to the dendrimer, and to the active agent(s) in
a
non-releasable manner. In an exemplary embodiment, one or more active
agent(s) is attached to the dendrimer via a spacer that is attached to the
dendrimer and the active agent(s) via amide and/or ether bonds. An
exemplary spacer is polyethylene glycol (PEG).
1. Dendrimer Conjugation to Active Agents via Ether
Linkages
In some embodiments, the compositions include a hydroxyl-
terminated dendrimer conjugated to an active agent via an ether linkage,
optionally with one or more linkers/spacers.
In preferred embodiments, the covalent bonds between the surface
groups of the dendrimers and the linkers, or the dendrimers and the active
agent (if conjugated without any linking moieties) are stable under in vivo
conditions, i.e., minimally cleavable when administered to a subject and/or
excreted intact from the body. For example, in preferred embodiments, less
than 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, or less than
0.1% of the total dendrimer complexes have active agent cleaved within 24
hours, or 48 hours, or 72 hours after in vivo administration. In one
embodiment, the covalent bonds are ether bonds. In further preferred
embodiments, the covalent bond between the surface groups of the
dendrimers and the linkers, or the dendrimers and the active agent (if
conjugated without any linking moieties), are not hydrolytically or
enzymatically cleavable bonds, such as ester bonds.
In some embodiments, one or more hydroxyl groups of hydroxyl-
terminated dendrimers conjugate to one or more linking moieties and one or
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
more active agents via one or more ether bonds as shown in Formula (I)
below.
(OH) m
\
D o¨LY¨X
In
Formula (I)
wherein D is a G2 to G10 poly(amidoamine) (PAMAM) dendrimer;
L is one or more linking moieties or spacers; X is an active agent or analog
thereof; n is an integer from 1 to 100; and m is an integer from 16 to 4096;
and
Y is a linker selected from secondary amides (-CONH-), tertiary
amides (-CONR-), sulfonamide (-S(0)2-NR-), secondary carbamates (-
OCONH-; -NHC00-), tertiary carbamates (-000NR-; -NRC00-),
carbonate (-0-C(0)-0-), ureas (-NHCONH-; -NRCONH-; -NHCONR-, -
NRCONR-), carbinols (-CHOH-, -CROH-), disulfide groups, hydrazones,
hydrazides, and ethers (-0-), wherein R is an alkyl group, an aryl group, or a
heterocyclic group. Preferably, Y is a bond or linkage that is minimally
cleavable in vivo.
In some embodiments, X is an inhibitor of vascular endothelial
growth factor receptor (VEGFR) and/or TIE2 receptor tyrosine kinases.
In a preferred embodiment, Y is a secondary amide (-CONH-).
In one embodiment, D is a generation 4 PAMAM dendrimer; L is one
or more linking or spacer moieties; X is sunitinib, or analog thereof; n is
about 5-15; m is an integer about 49-59; and where n+m=64.
In another embodiment, D is a generation 4 PAMAM dendrimer; L is
one or more linking or spacer moieties; X is N, N-didesethyl sunitinib; Y is a
secondary amide (-CONH-); n is about 5-15; m is an integer about 49-59;
and where n+m=64.
In a specific embodiment, the Formula I has the following structure
(also referred to as D-4517.2):
21
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Structure I: Chemical structure of D-4517.2
0
(01-4f,7
1
' e's
H '
D-4517:2
C. Therapeutic, Prophylactic and Diagnostic Agents
Dendrimers have the advantage that multiple therapeutic,
prophylactic, and/or diagnostic agents can be delivered with the same
dendrimers. In some embodiments, one or more types of active agents are
encapsulated, complexed or conjugated to the dendrimer. In another
embodiment, the dendrimers are covalently linked to at least one detectable
moiety, in an amount effective to detect one or more diseased or injured
cells/tissues in the subject. In particular embodiments, the dendrimer
composition has multiple agents, such as an immunotherapeutic agent, an
anti-seizure agent, a steroid to decrease swelling, an antibiotic, an anti-
angiogenic agent, and/or a diagnostic agent, complexed with or conjugated to
the dendrimers. In some embodiment, the dendrimers are complexed with or
conjugated to two or more different classes of active agents, providing
simultaneous delivery with different or independent release kinetics at the
target site. For example, both sunitinib and an anti-inflammatory agent can
be conjugated onto the same dendrimer for delivery to target cells/tissues. In
a further embodiment, dendrimer complexes each carrying different classes
of active agents are administered simultaneously for a combination
treatment. In some embodiments, one or more therapeutic agents targeting
the underlying cause of the disease or condition, and one or more therapeutic
agents relieving one or more symptoms of the disease or condition.
Suitable active agents include therapeutic, diagnostic, and/or
prophylactic agents. The agent can be a biomolecule, such as an enzyme,
protein, polypeptide, or nucleic acid or a small molecule agent (e.g.,
molecular weight less than 2000 Dalton, preferably less than 1500 Dalton,
more preferably 300-700 Dalton), including organic, inorganic, and
22
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
organometallic agents. The agent can be encapsulated within the
dendrimers, dispersed within the dendrimers, and/or associated with the
surface of the dendrimer, either covalently or non-covalently. Exemplary
therapeutic agents include anti-inflammatory drugs, anti-angiogenic agents,
anti-oxidants, vasodilators, neuroactive agents, neuroprotective agents and
anti-infective agents. In some embodiments, the dendrimer is linked to the
targeting moiety, imaging agents, and/or therapeutic agents via a linker or
spacer ending in disulfide, ester, ether, thioester, carbamate, carbonate,
hydrazine, or amide bonds.
The dendrimers can be used to deliver one or more additional active
agents, particularly one or more active agents to prevent or treat one or more
symptoms of the eye diseases. Exemplary therapeutic agents administered
with dendrimers include tyrosine kinase inhibitors such as VEGFR tyrosine
kinase inhibitors. In a preferred embodiment, the agents are small molecule
tyrosine kinase inhibitors.
Representative anti-angiogenesis agents include, but are not limited
to, antibodies to vascular endothelial growth factor (VEGF) such as
bevacizumab (AVASTINO) and rhuFAb V2 (ranibizumab, LUCENTISO),
and other anti-VEGF compounds including aflibercept (EYLEAO);
MACUGENO (pegaptanim sodium, anti-VEGF aptamer or EYE001)
(Eyetech Pharmaceuticals); pigment epithelium derived factor(s) (PEDF);
COX-2 inhibitors such as celecoxib (CELEBREXO) and rofecoxib
(VIOXXO); interferon alpha; interleukin-12 (IL-12); thalidomide
(THALOMIDO) and derivatives thereof such as lenalidomide
(REVLIMIDO); squalamine; endostatin; angiostatin; ribozyme inhibitors
such as ANGIOZYMEO (Sima Therapeutics); multifunctional
antiangiogenic agents such as NEOVASTATO (AE-941) (Aeterna
Laboratories, Quebec City, Canada); receptor tyrosine kinase (RTK)
inhibitors such as sunitinib (SUTENTO); tyrosine kinase inhibitors such as
sorafenib (NexavarO) and erlotinib (TarcevaO); antibodies to the epidermal
grown factor receptor such as panitumumab (VECTIBIXO) and cetuximab
(ERBITUXO), as well as other anti-angiogenesis agents known in the art.
23
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Other active agents suitable for anti-angiogenic therapies include
those targeting members of the platelet-derived growth factor family,
epidermal growth factor family, fibroblast growth factor family,
transforming growth factor-0 superfamily (TGF-01, activins, follistatin and
bone morphogenetic proteins), angiopoietin-like family, galectins family,
integrin superfamily, as well as pigment epithelium derived factor,
hepatocyte growth factor, angiopoietins, endothelins, hypoxia-inducible
factors, insulin-like growth factors, cytokines, matrix metalloproteinases and
their inhibitors and glycosylation proteins.
Tyrosine Kinase Inhibitor
In some embodiments, the dendrimers are complexed or conjugated
with one or more tyrosine kinase inhibitors.
Tyrosine kinases are important cellular signaling proteins that have a
variety of biological activities including cell proliferation and migration.
Multiple kinases are involved in angiogenesis, including receptor tyrosine
kinases such as the vascular endothelial growth factor receptor (VEGFR).
Anti-angiogenic tyrosine kinase inhibitors in clinical development primarily
target VEGFR-1, -2, -3, epidermal growth factor receptor (EGFR), platelet-
derived growth factor receptor (PDGFR), PDGFR-0, KIT, fms-related
tyrosine kinase 3 (FLT3), colony stimulating factor-1 receptor (CSF-1R),
Raf, and RET.
VEGFR Inhibitor
In some embodiments, the dendrimers are complexed or conjugated
with one or more VEGFR tyrosine kinase inhibitors. The VEGFR family
includes three related receptor tyrosine kinases, known as VEGFR-1, -2, and
-3, which mediate the angiogenic effect of VEGF ligands (Hicklin DJ, Ellis
LM. J Clin Oncol. (2005), 23(5):1011-27). The VEGF family encoded in the
mammalian genome includes five members: VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and placental growth factor (P1GF). VEGFs are important
stimulators of proliferation and migration of endothelial cells. Increased
expression of the angiogenic factor VEGF-A promotes three common aging-
related eye conditions ¨ "wet" and "dry" forms of age-related macular
24
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
degeneration and also cataracts in an animal model (Marneros AG, EMBO
Molecular Medicine, 2016; 8 (3): 208). Thus, in some embodiments,
dendrimers are conjugated to one or more active agents effective in reducing
the quantity and/or activity of one or more of VEGF-A, VEGF-B, VEGF-C,
VEGF-D, and placental growth factor (P1GF).
Most notable angiogenesis inhibitors target the vascular endothelial
growth factor signaling pathway, such as the monoclonal antibody
bevacizumab (AVASTIN , Genentech/Roche) and two kinase inhibitors
sunitinib (SU11248, SUTENT , Pfizer) and sorafenib (BAY43-9006,
NEXAVAR , Bayer). Bevacizumab was the first angiogenesis inhibitor that
was clinically approved, initially for treatment of colorectal cancer and
recently also for breast cancer and lung cancer. Another anti-VEGF agent
clinically available is pegaptanib sodium, an aptamer for neovascular AMD.
Unlike bevacizumab, which binds all VEGF isoforms, pegaptanib targets
only VEGF165, the isoform responsible for pathological ocular
neovascularization. In some embodiments, dendrimers are conjugated to one
or more VEGF inhibitors including bevacizumab and pegaptanib sodium.
The small-molecule tyrosine kinase inhibitors sunitinib and sorafenib
target the VEGF receptor (VEGFR), primarily VEGFR-2. Both drugs have
shown benefit in patients with renal cell cancer (Motzer RJ, Bukowski RM, J
Clin Oncol. (2006); 24(35):5601-8). Sunitinib is a potent inhibitor of
angiogenesis, with a rabbit model of corneal neovascularization suggesting
topical sunitinib is almost three times as effective as bevacizumab (Perez-
Santonj a JJ et al., Am J Ophthalmol. 2010 Oct;150(4):519-528). Sorafenib
inhibits Raf serine kinase. Cediranib is an oral tyrosine kinase inhibitor of
VEGF receptor (VEGFR).
In some embodiments, dendrimers are conjugated to one or more
VEGF receptor inhibitors including Sunitinib (SU11248; SUTENTC)),
Sorafenib (BAY439006; NEXAVARCI), Pazopanib (GW786034;
VOTRIENT ), Vandetanib (ZD6474; ZACTIMACI), Axitinib (AG013736),
Cediranib (AZD2171; RECENTINCI), Vatalanib (PTK787; ZK222584),
Dasatinib, Nintedanib, and Motesanib (AMG706). In preferred
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
embodiments, the VEGF receptor inhibitors can be functionalized with one
or more spacers/linkers, for example with ether, ester, or amide linkage, for
ease of conjugation with the dendrimers and/or for desired release kinetics.
For example, sunitinib can be modified to sunitinib with an ester linkage, or
with an amide linkage (FIGs. 1A and 1B). Exemplary conjugation of a
VEGF receptor inhibitor, e.g., sunitinib to a dendrimer is shown in FIG.1A
(via a hydroxymethyl linkage) and FIG. 1B (via an amide linkage). In
preferred embodiments, the conjugation of dendrimer and/or one or more
linkers does not significantly affect the activities of the active agents. In
further preferred embodiments, a VEGF receptor inhibitor is conjugated to
dendrimers with or without a spacer in such a way that it minimizes the
reduction in inhibition, for example, less than 1-fold, 2-fold, 3-fold, 4-
fold,
5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, and 100-fold. For example
in the case of sunitinib, it retains its binding affinity towards one or more
of
VEGFR TKR after conjugation to dendrimers at a level comparable to
unconjugated sunitinib.
Additional VEGF receptor inhibitors with a functional spacer/linkage
are shown below.
Structure II a-b: Chemical structures of Sorafenib analogues
H H
a N N
=-= N
F
H H
,N ,N
-I H
o
o
1-8
L.,
26
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Structure III a-d: Chemical structure of Nintedanib analogue 1
a b
.
N.,/
M$ ......-Ø.,....õ0 ..,....-, 0 =-=,..0 ..,,,ty,....0 ," y0 ...= ===.' '
\\,..244' 144 .."'... .-
6 t-e
..c,
0 ,
Nintedasibsamidnker wide
Ni ntecionAb-hydroenttiv/-80.er azi de
C d 9.
9
NI1 HN--11
,TlPi ,.. .r_..;
i >o
''-..-:µ'- \ it
,-=-= NH HN'
til ? ')'--
="--Th r 1 1.?
. /
......,
N A.-.,..----fo=----------1--
"C"'" N2
el
i\ 0µ11%-k, 0
1-8
Structure IV: Chemical structure of Orantinib analogue
i
r
1041-- n
"s.---
,'IN¨./
11,
11
0
Orantinib-amide-linker azide
In some embodiments, the dendrimer complexes including one or
more VEGF receptor inhibitors are administered in an amount effective to
reduce or inhibit endothelial cells angiogenesis and/or vascular endothelial
cell proliferation, to reduce retinal and/or choroidal angiogenesis and/or to
relieve to one or more of the symptoms associated with the disease or
disorder of the eye.
27
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
TIE II Antagonists
In some embodiments, the dendrimers are complexed or conjugated
with one or more inhibitors of TIE II. Angiopoietin-1 receptor, also known
as CD202B (cluster of differentiation 202B) and TIE II, is a protein that in
humans is encoded by the TEK gene. TIE2 is an angiopoietin receptor. The
angiopoietins are protein growth factors required for the formation of blood
vessels (angiogenesis), which supports tumor growth and development.
Therefore, in some embodiments, dendrimers are conjugated to one or more
TIE II antagonists.
In some embodiments, the active agents are inhibitors of TIE II
receptor tyrosine kinase. Exemplary inhibitors of VEGFR/TIE II include
CEP-11981 and rebastinib. The TIE II antagonists can be functionalized, for
example with ether, ester, ethyl, or amide linkage, for ease of conjugation
with the dendrimers and/or for desired release kinetics. The chemical
structure of an exemplary TIE II antagonist is shown below as Structure
XXI. TIE II inhibition of the free TIE II antagonist (Structure V) has a
dissociation constant, Kd, about 8.8 nm and the TIE II inhibition of
dendrimer conjugated TIE II antagonist (Structure XXI) has a dissociation
constant, Kd, about 25 nm. Thus, in preferred embodiments, TIE II
antagonists are conjugated to dendrimers with or without a spacer in such a
way that it minimizes the reduction in TIE II inhibition, for example, less
than 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-
fold,
50-fold, and 100-fold. In preferred embodiments, the active agents are
inhibitor of vascular endothelial growth factor receptor (VEGFR) and TIE II
receptor tyrosine kinases.
28
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Structure V: TIE II antagonist 1
cf: 3 0
H -o, i
,*o
õ="1-...s, 0
..,....
I r T
il-, 1
-----;;---3-- N
' -- N - N - `µ----
N'
H H
)
=µ1
$
i
N , Anti-inflammatory Agents
In some embodiments, one or more active agents associated with or
complexed to dendrimers are one or more anti-inflammatory agents. Anti-
inflammatory agents reduce inflammation and include steroidal and non-
steroidal drugs. Suitable steroidal active agents include glucocorticoids,
progestins, mineralocorticoids, and corticosteroids. In some embodiments,
one or more active agents are one or more corticosteroids.
Exemplary anti-inflammatory agents include triamcinolone
acetonide, fluocinolone acetonide, methylprednisolone, prednisolone,
dexamethasone, loteprendol, fluorometholone, ibuprofen, aspirin, and
naproxen. Exemplary immune-modulating drugs include cyclosporine,
tacrolimus and rapamycin. Exemplary non-steroidal anti-inflammatory drugs
(NSAIDs) include mefenamic acid, aspirin, Diflunisal, Salsalate, Ibuprofen,
Naproxen, Fenoprofen, Ketoprofen, Deacketoprofen, Flurbiprofen,
Oxaprozin, Loxoprofen, Indomethacin, Sulindac, Etodolac, Ketorolac,
Diclofenac, Nabumetone, Piroxicam, Meloxicam, Tenoxicam, Droxicam,
Lomoxicam, Isoxicam, Meclofenamic acid, Flufenamic acid, Tolfenamic
acid, elecoxib, Rofecoxib, Valdecoxib, Parecoxib, Lumiracoxib, Etoricoxib,
Firocoxib, Sulphonanilides, Nimesulide, Niflumic acid, and Licofelone. In
preferred embodiments, the active agent is triamcinolone acetonide,
prednisolone, dexamethasone, or analogues thereof. Exemplary analogues of
triamcinolone acetonide, prednisolone, and dexamethasone are shown below.
29
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Structure VI a-f: Chemical structure of analogues of triamcinolone
acetonide, prednisolone, dexamethasone
q
r1 1131(2 ..,./0..e,õ.,,,;(0,,s,,-,oxr.õ,,E1- mg =... p"Nio--
--'0)--N--- -
411 ij ' . = ,4
, -...--:---1
1 F Ft 11-8
cy,,,,,õ:...---..,,,,,
cr:::,!,...c.õ:-.--,,..._.-=
a flexacimfbasorke aneiogue? b Dexametrowle a rolo que
Os
0,,,,,-, = = ' 1 -,o
C:1¨r2:14-i
1 1_1-4 1
<, > r 0, , , A A L
C Prosinisdne atuilogue -
d Tilamdrolone atetonide nalogue
0 o
..
..µ_
.1.
=.> _.A. a
/ A 1 OH
=/.
H \ )o
OH.'-' N` '0 i
'170 1-8
bH b-f,,
Y
e Iliamfinatone acetonide ardague I Triarkultiolorte aWoriltio
analogue
In some embodiments, the active agent is N-acetyl-L-cysteine, or a
derivative or analogue or prodrug thereof. In a preferred embodiment, N-
acetyl-L-cysteine is conjugated to a hydroxyl-terminated PAMAM
dendrimer via non-cleavable linkage for minimal release of free N-acetyl-
cysteine after in vivo administration. The synthesis route for an exemplary
non-releasable (or non-cleavable) form of the dendrimer/N-acetyl-cysteine
complexes is shown in FIG. 14. In one embodiment, the dendrimer complex
is dendrimer-NAC-carboxymethylated conjugate as shown in FIG.14. The
non-releasable form of the dendrimer/ N-acetyl-cysteine complex provides
enhanced therapeutic efficacy as compared to a releasable or cleavable form
of the dendrimer/N-acetyl-cysteine complex, for example, N-acetyl-L-
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
cysteine conjugated to a hydroxyl-terminated PAMAM dendrimer via an
ester linkage.
In some embodiments, one or more active agents are polysialic acid
(e.g., low molecular weight polySia with an average degree of
polymerization 20 (polySia avDP20)), Translocator Protein Ligands (e.g.,
Diazepam binding inhibitor (DBI)), Interferon-0 (IFN-0), and minocycline.
In some cases, one or more active agents are anti-infective agents.
Exemplary anti-infectious agents include antiviral agents, antibacterial
agents, antiparasitic agents, and anti-fungal agents. Exemplary antibiotics
include moxifloxacin, ciprofloxacin, erythromycin, levofloxacin, cefazolin,
vancomycin, tigecycline, gentamycin, tobramycin, ceftazidime, ofloxacin,
gatifloxacin; antifungals: amphotericin, voriconazole, natamycin.
Diagnostic Agents
Dendrimer nanoparticles can include diagnostic agents useful for
determining the location of administered particles. These agents can also be
used prophylactically. In some embodiments, dendrimers are conjugated to
one or more diagnostic agents including indocyanine green, fluorescein (e.g.,
fluorescein isocyanate), boron-dipyrromethene, rhodamine, and rose Bengal.
In preferred embodiments, the diagnostic agent is indocyanine green as
shown below:
Structure VII: Chemical structure of indocyanine green
N
o=s =
so
isss
Indocyanine Green
Additional examples of diagnostic agents include paramagnetic
molecules, fluorescent compounds, magnetic molecules, and radionuclides,
x-ray imaging agents, and contrast media. Examples of other suitable
31
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
contrast agents include gases or gas emitting compounds, which are
radioopaque. Dendrimer complexes can further include agents useful for
determining the location of administered compositions. Agents useful for
this purpose include fluorescent tags, radionuclides and contrast agents.
Exemplary diagnostic agents include dyes such as fluorescent dyes
and near infra-red dyes, SPECT imaging agents, PET imaging agents and
radioisotopes. Representative dyes include carbocyanine, indocarbocyanine,
oxacarbocyanine, thilicarbocyanine and merocyanine, polymethine,
coumarine, rhodamine, xanthene, fluorescein, boron-dipyrromethane
(BODIPY), Cy5, Cy5.5, Cy7, VivoTag-680, VivoTag-S680, VivoTag-S750,
AlexaFluor660, AlexaFluor680, AlexaFluor700, AlexaFluor750,
AlexaFluor790, Dy677, Dy676, Dy682, Dy752, Dy780, DyLight547,
Dylight647, HiLyte Fluor 647, HiLyte Fluor 680, HiLyte Fluor 750, IRDye
800CW, IRDye 800RS, IRDye 700DX, ADS780WS, ADS830WS, and
ADS832WS.
Exemplary SPECT or PET imaging agents include chelators such as
di-ethylene tri-amine penta-acetic acid (DTPA), 1,4,7,10-tetra-
azacyclododecane-1,4,7,10-tetraacetic acid (DOTA), di-amine dithiols,
activated mercaptoacetyl-glycyl-glycyl-gylcine (MAG3), and
hydrazidonicotinamide (HYNIC).
Exemplary isotopes include Tc-94m, Tc-99m, In-111, Ga-67, Ga-68,
Gd3+, Y-86, Y-90, Lu-177, Re-186, Re-188, Cu-64, Cu-67, Co-55, Co-57,
F-18, Sc-47, Ac-225, Bi-213, Bi-212, Pb-212, Sm-153, Ho-166, and Dy-166.
In preferred embodiments, the dendrimer complex includes one or
more radioisotopes suitable for positron emission tomography (PET)
imaging. Exemplary positron-emitting radioisotopes include carbon-11 (11C),
copper-64 (64Cu), nitrogen-13 (13N), oxygen-15 (150), gallium-68 (68Ga), and
fluorine-18 (18F), e.g., 2-deoxy-2-18F-fluoro-3-D-glucose (18F-FDG).
In preferred embodiments, the one or more diagnostic agents can be
functionalized with one or more spacers/linkers, for example with ether,
ester, or amide linkage, for ease of conjugation with the dendrimers and/or
for desired release kinetics.
32
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
In further embodiments, a singular dendrimer complex composition
can simultaneously treat, and/or diagnose a disease or a condition at one or
more locations in the body.
III. Pharmaceutical Formulations
Pharmaceutical compositions including one or more dendrimer
complexes may be formulated in a conventional manner using one or more
physiologically acceptable carriers including excipients and auxiliaries
which facilitate processing of the active compounds into preparations which
can be used pharmaceutically. Proper formulation is dependent upon the
route of administration chosen. Pharmaceutical formulations contain one or
more dendrimer complexes in combination with one or more
pharmaceutically acceptable excipients. Representative excipients include
solvents, diluents, pH modifying agents, preservatives, antioxidants,
suspending agents, wetting agents, viscosity modifiers, tonicity agents,
stabilizing agents, and combinations thereof. Suitable pharmaceutically
acceptable excipients are preferably selected from materials which are
generally recognized as safe (GRAS), and may be administered to an
individual without causing undesirable biological side effects or unwanted
interactions.
In preferred embodiments, the compositions are formulated for
parenteral delivery to the eye. In some embodiments, the compositions are
formulated for subcutaneous or intravitreal injection. Typically the
compositions will be formulated in sterile saline or buffered solution for
injection into the tissues or cells to be treated. The compositions can be
stored lyophilized in single use vials for rehydration immediately before use.
Other means for rehydration and administration are known to those skilled in
the art.
Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams &
Wilkins, Baltimore, MD, 2000, p. 704, provides suitable formulations and
examples of ophthalmic drugs administered in the form of a
pharmaceutically acceptable salt include timolol maleate, brimonidine
tartrate, and sodium diclofenac.
33
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
The compositions are preferably formulated in dosage unit form for
ease of administration and uniformity of dosage. The phrase "dosage unit
form" refers to a physically discrete unit of conjugate appropriate for the
patient to be treated. It will be understood, however, that the total single
administration of the compositions will be decided by the attending
physician within the scope of sound medical judgment. The therapeutically
effective dose can be estimated initially either in cell culture assays or in
animal models, usually mice, rabbits, dogs, or pigs. The animal model is also
used to achieve a desirable concentration range and route of administration.
Such information should then be useful to determine useful doses and routes
for administration in humans. Therapeutic efficacy and toxicity of conjugates
can be determined by standard pharmaceutical procedures in cell cultures or
experimental animals, e.g., ED50 (the dose is therapeutically effective in
50% of the population) and LD50 (the dose is lethal to 50% of the
population). The dose ratio of toxic to therapeutic effects is the therapeutic
index and it can be expressed as the ratio, LD50/ED50. Pharmaceutical
compositions which exhibit large therapeutic indices are preferred. The data
obtained from cell culture assays and animal studies can be used in
formulating a range of dosages for human use.
Pharmaceutical compositions formulated for administration by
parenteral (intramuscular, intraperitoneal, intravenous or subcutaneous
injection) and enteral routes of administration are described. In preferred
embodiments, the compositions are administered via a systemic
administration. In one embodiment, the compositions are administered via
subcutaneous route. In another embodiment, the compositions are
administered orally.
A. Parenteral Administration
The phrases "parenteral administration" and "administered
parenterally" are art-recognized terms, and include modes of administration
other than enteral and topical administration, such as injections, and include
without limitation intravenous, intramuscular, intrapleural, intravascular,
intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital,
34
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
intracardiac, intradennal, intraperitoneal, transtracheal, subcutaneous,
subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and
intrastemal injection and infusion. In some embodiments, the dendrimers are
administered parenterally, for example, by subdural, intravenous, intrathecal,
intraventricular, intraarterial, intra-amniotic, intraperitoneal, or
subcutaneous
routes. In preferred embodiments, the dendrimer compositions are
administered via subcutaneous injection.
For liquid formulations, pharmaceutically acceptable carriers may be,
for example, aqueous or non-aqueous solutions, suspensions, emulsions or
oils. Parenteral vehicles include, for example, sodium chloride solution,
Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed
oils. Examples of non-aqueous solvents are propylene glycol, polyethylene
glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers
include, for example, water, alcoholic/aqueous solutions, cyclodextrins,
emulsions or suspensions, including saline and buffered media. The
dendrimers can also be administered in an emulsion, for example, water in
oil. Examples of oils are those of petroleum, animal, vegetable, or synthetic
origin, for example, peanut oil, soybean oil, mineral oil, olive oil,
sunflower
oil, fish-liver oil, sesame oil, cottonseed oil, corn oil, olive, petrolatum,
and
mineral. Suitable fatty acids for use in parenteral formulations include, for
example, oleic acid, stearic acid, and isostearic acid. Ethyl oleate and
isopropyl myristate are examples of suitable fatty acid esters.
Formulations suitable for parenteral administration can include
antioxidants, buffers, bacteriostats, and solutes that render the formulation
isotonic with the blood of the intended recipient, and aqueous and
non-aqueous sterile suspensions that can include suspending agents,
solubilizers, thickening agents, stabilizers, and preservatives. Intravenous
vehicles can include fluid and nutrient replenishers, electrolyte replenishers
such as those based on Ringer's dextrose. In general, water, saline, aqueous
dextrose and related sugar solutions, and glycols such as propylene glycols
or polyethylene glycol are preferred liquid carriers, particularly for
injectable
solutions.
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Injectable pharmaceutical carriers are well-known to those of
ordinary skill in the art (see, e.g., Pharmaceutics and Pharmacy Practice,
J.B.
Lippincott Company, Philadelphia, PA, Banker and Chalmers, eds., pages
238-250 (1982), and ASHP Handbook on Injectable Drugs, Trissel, 15th ed.,
pages 622-630 (2009)).
B. Enteral Administration
In some embodiments, the compositions are formulated to be
administered enterally. The carriers or diluents may be solid carriers such as
capsule or tablets or diluents for solid formulations, liquid carriers or
diluents
for liquid formulations, or mixtures thereof.
For liquid formulations, pharmaceutically acceptable carriers may be,
for example, aqueous or non-aqueous solutions, suspensions, emulsions or
oils. Examples of non-aqueous solvents are propylene glycol, polyethylene
glycol, and injectable organic esters such as ethyl oleate. Aqueous carriers
include, for example, water, alcoholic/aqueous solutions, cyclodextrins,
emulsions or suspensions, including saline and buffered media.
Examples of oils are those of petroleum, animal, vegetable, or
synthetic origin, for example, peanut oil, soybean oil, mineral oil, olive
oil,
sunflower oil, fish-liver oil, sesame oil, cottonseed oil, corn oil, olive,
petrolatum, and mineral. Suitable fatty acids for use in parenteral
formulations include, for example, oleic acid, stearic acid, and isostearic
acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid
esters.
Vehicles include, for example, sodium chloride solution, Ringer's
dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
Formulations include, for example, aqueous and non-aqueous, isotonic
sterile injection solutions, which can contain antioxidants, buffers,
bacteriostats, and solutes that render the formulation isotonic with the blood
of the intended recipient, and aqueous and non-aqueous sterile suspensions
that can include suspending agents, solubilizers, thickening agents,
stabilizers, and preservatives. Vehicles can include, for example, fluid and
nutrient replenishers, electrolyte replenishers such as those based on
Ringer's
36
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
dextrose. In general, water, saline, aqueous dextrose and related sugar
solutions are preferred liquid carriers. These can also be formulated with
proteins, fats, saccharides and other components of infant formulas.
In preferred embodiments, the compositions are formulated for oral
administration. Oral formulations may be in the form of chewing gum, gel
strips, tablets, capsules or lozenges. Encapsulating substances for the
preparation of enteric-coated oral formulations include cellulose acetate
phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose
phthalate and methacrylic acid ester copolymers. Solid oral formulations
such as capsules or tablets are preferred. Elixirs and syrups also are well
known oral formulations.
IV. Methods of Making
A. Methods of Making Dendrimers
Dendrimers can be prepared via a variety of chemical reaction steps.
Dendrimers are usually synthesized according to methods allowing
controlling their structure at every stage of construction. The dendritic
structures are mostly synthesized by two main different approaches:
divergent or convergent.
In some embodiments, dendrimers are prepared using divergent
methods, in which the dendrimer is assembled from a multifunctional core,
which is extended outward by a series of reactions, commonly a Michael
reaction. The strategy involves the coupling of monomeric molecules that
possesses reactive and protective groups with the multifunctional core
moiety which leads to stepwise addition of generations around the core
followed by removal of protecting groups. For example, PAMAM-NH2
dendrimers are first synthesized by coupling N-(2-aminoethyl) acryl amide
monomers to an ammonia core.
In other embodiments, dendrimers are prepared using convergent
methods, in which dendrimers are built from small molecules that end up at
the surface of the sphere, and reactions proceed inward building inward and
are eventually attached to a core.
37
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Many other synthetic pathways exist for the preparation of
dendrimers, such as the orthogonal approach, accelerated approaches the
Double-stage convergent method or the hypercore approach, the
hypermonomer method or the branched monomer approach, the Double
exponential method; the Orthogonal coupling method or the two-step
approach, the two monomers approach, AB2¨CD2 approach.
In some embodiments, the core of the dendrimer, one or more
branching units, one or more linkers/spacers, and/or one or more surface
groups can be modified to allow conjugation to further functional groups
(branching units, linkers/spacers, surface groups, etc.), monomers, and/or
active agents via click chemistry, employing one or more Copper-Assisted
Azide-Alkyne Cycloaddition (CuAAC), Diels-Alder reaction, thiol-ene and
thiol-yne reactions, and azide-alkyne reactions (Arseneault M et al.,
Molecules. 2015 May 20;20(5):9263-94). In some embodiments, pre-made
dendrons are clicked onto high-density hydroxyl polymers. 'Click
chemistry' involves, for example, the coupling of two different moieties
(e.g., a core group and a branching unit; or a branching unit and a surface
group) via a 1,3-dipolar cycloaddition reaction between an alkyne moiety (or
equivalent thereof) on the surface of the first moiety and an azide moiety
(e.g., present on a triazine composition) (or equivalent thereof) (or any
active
end group such as, for example, a primary amine end group, a hydroxyl end
group, a carboxylic acid end group, a thiol end group, etc.) on the second
moiety.
In some embodiments, dendrimer synthesis replies upon one or more
reactions selected from thiol-ene click reactions, thiol-yne click reactions,
CuAAC, Diels-Alder click reactions, azide-alkyne click reactions, Michael
Addition, epoxy opening, esterification, silane chemistry, and a combination
thereof.
Any existing dendritic platforms can be used to make dendrimers of
desired functionalities, i.e., with a high-density of surface hydroxyl groups
by conjugating high-hydroxyl containing moieties such as 1-thio-glycerol or
pentaerythritol. Exemplary dendritic platforms such as polyamidoamine
38
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
(PAMAM), poly (propylene imine) (PPI), poly-L-lysine, melamine, poly
(etherhydroxylamine) (PEHAM), poly (esteramine) (PEA) and polyglycerol
can be synthesized and explored.
Still further, suitable dendrimers can be prepared by combining two
or more dendrons. Dendrons are wedge-shaped sections of dendrimers with
reactive focal point functional groups. Many dendron scaffolds are
commercially available. They come in 1, 2, 3, 4, 5, and 6th generations with,
respectively, 2, 4, 8, 16, 32, and 64 reactive groups. In certain examples,
one
type of active agents are linked to one type of dendron and a different type
of
active agents are linked to another type of dendron. The two dendrons are
then connected to form a dendrimer. The two dendrons can be linked via
click chemistry i.e., a 1,3-dipolar cycloaddition reaction between an azide
moiety on one dendron and alkyne moiety on another to form a triazole
linker.
Exemplary methods of making dendrimers are described in detail in
International Patent Publication Nos. W02009/046446, W02015168347,
W02016025745, W02016025741, W02019094952, and U.S. Patent No.
8,889,101.
B. Dendrimer Complexes
Dendrimer complexes can be formed of therapeutically active agents
or compounds conjugated or attached to a dendrimer, a dendritic polymer or
a hyperbranched polymer. Techniques for conjugation of one or more active
agents to a dendrimer are known in the art, and are described in detail in
U.S.
Published Application Nos. US 2011/0034422, US 2012/0003155, and US
2013/0136697.
In some embodiments, one or more active agents are covalently
attached to the dendrimers. In some embodiments, the active agents are
attached to the dendrimer via a linking moiety that is designed to be cleaved
in vivo. The linking moiety can be designed to be cleaved hydrolytically,
enzymatically, or combinations thereof, so as to provide for the sustained
release of the active agents in vivo. Both the composition of the linking
moiety and its point of attachment to the active agent, are selected so that
39
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
cleavage of the linking moiety releases either an active agent, or a suitable
prodrug thereof. The composition of the linking moiety can also be selected
in view of the desired release rate of the active agents.
In some embodiments, the attachment occurs via one or more of
disulfide, ester, ether, thioester, carbamate, carbonate, hydrazine, or amide
linkages. In preferred embodiments, the attachment occurs via an appropriate
spacer that provides an ester bond or an amide bond between the agent and
the dendrimer depending on the desired release kinetics of the active agent.
In some cases, an ester bond is introduced for cleavable form of active
agents. In other cases, an amide bond is introduced for non-cleavable form of
active agents. Exemplary synthesis routes are described in Example 4 and 5
to show introduction of non-cleavable linkages between active agents and
dendrimers.
Linking moieties generally include one or more organic functional
groups. Examples of suitable organic functional groups include secondary
amides (-CONH-), tertiary amides (-CONR-), sulfonamide (-S(0)2-NR-),
secondary carbamates (-000NH-; -NHC00-), tertiary carbamates (-
OCONR-; -NRC00-), carbonate (-0-C(0)-0-), ureas (-NHCONH-; -
NRCONH-; -NHCONR-, -NRCONR-), carbinols (-CHOH-, -CROH-),
disulfide groups, hydrazones, hydrazides, ethers (-0-), and esters (-000-, ¨
CH202C-, CHRO2C-), wherein R is an alkyl group, an aryl group, or a
heterocyclic group. In general, the identity of the one or more organic
functional groups within the linking moiety can be chosen in view of the
desired release rate of the active agents. In addition, the one or more
organic
functional groups can be chosen to facilitate the covalent attachment of the
active agents to the dendrimers. In preferred embodiments, the attachment
can occur via an appropriate spacer that provides a disulfide bridge between
the agent and the dendrimer. The dendrimer complexes are capable of rapid
release of the agent in vivo by thiol exchange reactions, under the reduced
conditions found in body.
In certain embodiments, the linking moiety includes one or more of
the organic functional groups described above in combination with a spacer
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
group. The spacer group can be composed of any assembly of atoms,
including oligomeric and polymeric chains; however, the total number of
atoms in the spacer group is preferably between 3 and 200 atoms, more
preferably between 3 and 150 atoms, more preferably between 3 and 100
atoms, most preferably between 3 and 50 atoms. Examples of suitable
spacer groups include alkyl groups, heteroalkyl groups, alkylaryl groups,
oligo- and polyethylene glycol chains, and oligo- and poly(amino acid)
chains. Variation of the spacer group provides additional control over the
release of the anti-inflammatory agents in vivo. In embodiments where the
linking moiety includes a spacer group, one or more organic functional
groups will generally be used to connect the spacer group to both the anti-
inflammatory agent and the dendrimers.
Reactions and strategies useful for the covalent attachment of active
agents to dendrimers are known in the art. See, for example, March,
"Advanced Organic Chemistry," 5th Edition, 2001, Wiley-Interscience
Publication, New York) and Hermanson, "Bioconjugate Techniques," 1996,
Elsevier Academic Press, U.S.A. Appropriate methods for the covalent
attachment of a given active agent can be selected in view of the linking
moiety desired, as well as the structure of the active agents and dendrimers
as a whole as it relates to compatibility of functional groups, protecting
group strategies, and the presence of labile bonds.
The optimal drug loading will necessarily depend on many factors,
including the choice of drug, dendrimer structure and size, and tissues to be
treated. In some embodiments, the one or more active drugs are
encapsulated, associated, and/or conjugated to the dendrimer at a
concentration of about 0.01% to about 45%, preferably about 0.1% to about
30%, about 0.1% to about 20%, about 0.1% to about 10%, about 1% to about
10%, about 1% to about 5%, about 3% to about 20% by weight, and about
3% to about 10% by weight. However, optimal drug loading for any given
drug, dendrimer, and site of target can be identified by routine methods, such
as those described.
41
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
In some embodiments, conjugation of active agents and/or linkers
occurs through one or more surface and/or interior groups. Thus, in some
embodiments, the conjugation of active agents/linkers occurs via about 1%,
2%, 3%, 4%, or 5% of the total available surface functional groups,
preferably hydroxyl groups, of the dendrimers prior to the conjugation. In
other embodiments, the conjugation of active agents/linkers occurs on less
than 5%, less than 10%, less than 15%, less than 20%, less than 25%, less
than 30%, less than 35%, less than 40%, less than 45%, less than 50%, less
than 55%, less than 60%, less than 65%, less than 70%, less than 75% total
available surface functional groups of the dendrimers prior to the
conjugation. In preferred embodiments, dendrimer complexes retain an
effective amount of surface functional groups for targeting to specific cell
types, whilst conjugated to an effective amount of active agents for treat,
prevent, and/or image the disease or disorder.
1. Dendrimer Conjugation to Active Agents via Ether
Linkages
A method to incorporate one or more active agents onto a hydroxyl-
terminated dendrimer via an ether linkage, optionally via one or more
linkers/spacers, has been developed.
In some embodiments, surface or terminal groups of hydroxyl-
terminated dendrimers are modified via etherification reaction prior to
conjugation to one or more linkers/spacers and one or more radionuclides.
Etherification is the dehydration of an alcohol to form ethers. In some
embodiments, one or more hydroxyl groups of hydroxyl-terminated
dendrimers undergo etherification reaction prior to conjugation to one or
more linking moieties and one or more active agents.
In some embodiments, ether linkage is introduced at the surface
groups of hydroxyl PAMAM dendrimer by reacting with propargyl bromide
in the presence of 2% sodium hydroxide solution in DMSO. In a further
embodiment, etherification reaction of generation 4 hydroxyl-terminated
PAMAM dendrimer, PAMAM-G4-0H, using allyl bromide, anhydrous
cesium carbonate and tetrabutylammonium iodide in DMF.
42
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
In other embodiments, at dendrimer generation 3.5, alkyne functional
groups are introduced using a polyethyl glycol (PEG) linker with an amine at
one end and a hexyne at the other end to produce a generation 4 bifunctional
dendrimer, i.e., with hydroxyl groups and ether linkages ready for further
conjugation. An exemplary bifunctional dendrimer is shown as compound 1
in FIG. 11 with 7 alkyne arms and 57 hydroxyl groups on the surface.
V. Methods of Use
The dendrimer complex compositions are generally suitable for
treatment of one or more diseases or disorders associated with the eye,
particularly inflammatory and/or angiogenic diseases in the eye. Dendrimer
compositions and methods thereof for targeted delivery of one or more active
agents to the diseased tissues/cells in the eye via systemic administration
with increased efficacy and reduced side effects are described, preferably via
selectively targeting to affected cells/tissue including activated microglia
and
activated macrophage, retinal pigment epithelia (RPE) cells, and/or choroidal
neovascular (CNV) lesions. Preferably dendrimer compositions and methods
thereof for targeted delivery give rise to minimal dendrimer in non-injured
region of optic nerve or CNS. Methods for treating back of the eye disorders
are also described. In some embodiments, the dendrimer complexes are used
to treat exudative form of age-related macular degeneration (AMD). The
methods typically include administering a subject in a need thereof an
effective amount of a composition including dendrimer and one or more
active agents.
Methods of reducing and/or inhibiting the number or activities of
activated microglia and macrophages in the retina and/or the choroid in the
eye of a subject in need thereof are provided. In some embodiments,
treatment using an effective amount of the compositions including hydroxyl-
terminated dendrimer complexed, covalently conjugated or intra-molecularly
dispersed or encapsulated with one or more therapeutic agents is
administered to reduce and/or inhibit the number or activities of the
activated
microglia and macrophages in the retina and/or the choroid in the eye in need
thereof. In some embodiments, the compositions are administered in a
43
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
dosage and via a route to inhibit or reduce activation of microglia in the
retina. In other embodiments, compositions can inhibit or reduce phagocytic
activities of microglia. In other embodiments, compositions including one or
more receptor tyrosine kinase inhibitors can inhibit or reduce activity and/or
quantity of activated microglia and macrophages in the diseased retina and/or
choroid of a subject by about 10%, 20%, 30%, 40%, 50%, 75%, 85%, 90%,
95%, or 99% compared to the activity and/or quantity of the same cells in
equivalent diseased tissues of subjects that did not receive, or were not
treated with the dendrimer compositions (e.g., un-conjugated active agents).
Methods of reducing and/or inhibiting the expression and/or activities
of VEGF and/or VEGFR in the activated microglia, activated macrophages,
and/or retinal pigment epithelial (RPE) cells in the diseased retina and/or
choroid are also described. In some embodiments, the compositions are
applied via systemic routes such as intravenous injections, subcutaneous
injections or oral administration. In preferred embodiments, the compositions
are not administered intravitreally or subchoroidally, which can result in
direct damage and/or inflammation to the eye. Methods of reducing and/or
inhibiting one or more pro-inflammatory cytokines secreted by the activated
microglia and macrophages in the diseased retina and/or choroid are also
described. In some embodiments, treatment using an effective amount of the
compositions leads to a decrease in expression of one or more pro-
inflammatory cytokines (e.g., TNF-a, interleukin-10 (IL-113), or interferon-y
(IFN-y)) secreted by the activated microglia and macrophages in the diseased
retina and/or choroid by about 10%, 20%, 30%, 40%, 50%, 75%, 85%, 90%,
95%, or 99% compared to those in equivalent diseased tissues of subjects
that did not receive, or were not treated with the dendrimer compositions
(e.g., un-conjugated active agents).
Methods of reducing and/or inhibiting one or more pro-oxidative
properties of the activated microglia and macrophages in the diseased retina
and/or choroid are also described. In some embodiments, treatment using an
effective amount of the compositions leads to a decrease in the oxidative
stress of the activated microglia and macrophages in the diseased retina
44
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
and/or choroid, for example by reducing nitric oxide (NO) production or
inducible nitric oxide synthase (iNOS) activation (e.g., NOS2 expression),
by about 10%, 20%, 30%, 40%, 50%, 75%, 85%, 90%, 95%, or 99%
compared to those in equivalent diseased tissues of subjects that did not
receive, or were not treated with the dendrimer compositions (e.g., un-
conjugated active agents).
Methods of reducing and/or inhibiting abnormal vascular
permeability and leakage, and/or neoangiogenesis in the eye of a subject in
need thereof are also described. In some embodiments, treatment using an
effective amount of the compositions leads to a decrease in vascular leakage
and/or neoangiogenesis.
A. Treatment Regimen
1. Dosage and Effective Amounts
Dosage and dosing regimens are dependent on the severity and
location of the disorder or injury and/or methods of administration, and are
known to those skilled in the art. A therapeutically effective amount of the
dendrimer composition used in the treatment of one or more eye diseases is
typically sufficient to treat, inhibit, or alleviate one or more symptoms
associated with the eye.
In some in vivo approaches, the dendrimer complexes are
administered to a subject in a therapeutically effective amount to reduce or
inhibit ocular angiogenesis, particularly retinal and choroidal
neovascularization. In some embodiments, an effective amount of the
composition is used to reduce or inhibit endothelial cells angiogenesis and/or
vascular endothelial cell proliferation.
A pharmaceutical composition including a therapeutically effective
amount of the dendrimer compositions and a pharmaceutically acceptable
diluent, carrier or excipient is described. In some embodiments, the
pharmaceutical composition includes an effective amount of hydroxyl-
terminated dendrimers conjugated to a VEGF receptor tyrosine kinase
inhibitor. In some particular embodiments, dosage ranges suitable for
parenteral use are between about 0.1 mg/kg and about 200 mg/kg, inclusive;
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
between about 0.5 mg/kg and about 100 mg/kg, inclusive; between about 1.0
mg/kg and about 40 mg/kg, inclusive; and between about 2.0 mg/kg and
about 20 mg/kg, inclusive. Higher doses may be given initially to load the
patient with drug and maximize uptake in the diseased tissues (e.g. eye).
After the loading dose, patients may receive a maintenance dose. Loading
doses may range from 10 to 100 mg/kg of body weight and maintenance
doses may range from 0.1 to <10 mg/kg of body weight. When administered
enterally, the dose required for treatment may be up to 10 fold greater than
the effective parenteral dose. The optimal dose is selected from the safety
and efficacy results of each tested dose for each drug in patients.
Dosage forms of the pharmaceutical composition including the
dendrimer compositions are also provided. "Dosage form" refers to the
physical form of a dose of a therapeutic compound, such as a capsule or vial,
intended to be administered to a patient. The term "dosage unit" as used
herein refers to the amount of the therapeutic compounds to be administered
to a patient in a single dose. In some embodiments, the dosage unit suitable
for use are (assuming the weight of an average patient being 70 kg) between
5 mg/dosage unit and about 14,000 mg/ dosage unit, inclusive; between
about 35 mg/ dosage unit and about 7,000 mg/ dosage unit, inclusive; and
between about 70 mg/ dosage unit and about 2,800 mg/ dosage unit,
inclusive; and between about 140 mg/ dosage unit and about 1,400 mg/
dosage unit, inclusive.
The actual effective amounts of dendrimer complex can vary
according to factors including the specific active agent administered, the
particular composition formulated, the mode of administration, and the age,
weight, condition of the subject being treated, as well as the route of
administration and the disease or disorder.
Preferably the dendrimer compositions including one or more active
agents, for example sunitinib, are delivered to cells in and around the
diseases or injured tissues, (e.g. microglia). For example, dendrimer complex
compositions can be in an amount effective to deliver one or more active
agents to cells at or nearby the site of inflammation, particularly
46
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
inflammation of the eye. Therefore, in some embodiments, the dendrimer
complex compositions including one or more active agent are in an amount
effective to ameliorate inflammation in a subject. In a preferred
embodiment, the effective amount of dendrimer complex compositions does
not induce significant cytotoxicity in the cells of a subject compared to an
untreated control subject. Preferably, the amount of dendrimer complex
compositions is effective to prevent or reduce inflammation and/or further
associated symptoms of a disease or disorder in a subject compared to an
untreated control.
In general, the timing and frequency of administration will be
adjusted to balance the efficacy of a given treatment or diagnostic schedule
with the side-effects of the given delivery system. Exemplary dosing
frequencies include continuous infusion, single and multiple administrations
such as hourly, daily, weekly, monthly or yearly dosing.
In some embodiments, dosages are administered once, twice, or three
times daily, or less frequently, for example, every other day, two days, three
days, four days, five days, or six days to a human. In some embodiments,
dosages are administered only about once or twice every week, every two
weeks, every three weeks, or every four weeks. In some embodiments,
dosages are administered about once or twice every month, every two
months, every three months, every four months, every five months, or every
six months, or less frequent. In a preferred embodiment, dosages are
administered once every four weeks or less frequent.
It will be understood by those of ordinary skill that a dosing regimen
can be any length of time sufficient to treat the disorder in the subject. In
some embodiments, the regimen includes one or more cycles of a round of
therapy followed by a drug holiday (e.g., no drug). The round of the therapy
can be, for example, and of the administrations discussed above. Likewise,
the drug holiday can be 1, 2, 3, 4, 5, 6, or 7 days; or 1, 2, 3, 4 weeks, or
1, 2,
3,4, 5, or 6 months.
47
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
2. Controls
The therapeutic result of the dendrimer complex compositions
including one or more active agents can be compared to a control. Suitable
controls are known in the art and include, for example, untreated cells or an
untreated subject. A typical control is a comparison of a condition or
symptom of a subject prior to and after administration of the targeted agent.
The condition or symptom can be a biochemical, molecular, physiological,
or pathological readout. For example, the effect of the composition on a
particular symptom, pharmacologic, or physiologic indicator can be
compared to an untreated subject, or the condition of the subject prior to
treatment. In some embodiments, the symptom, pharmacologic, or
physiologic indicator is measured in a subject prior to treatment, and again
one or more times after treatment is initiated. In some embodiments, the
control is a reference level, or average determined based on measuring the
symptom, pharmacologic, or physiologic indicator in one or more subjects
that do not have the disease or condition to be treated (e.g., healthy
subjects).
In some embodiments, the effect of the treatment is compared to a
conventional treatment that is known the art.
B. Subjects to be Treated
The compositions and methods are suitable for treatment one or more
diseases or disorders of the eye. The compositions and methods are suitable
for alleviating one or more symptoms associated with one or more diseases
or disorder of the eye, for example, discomfort, pain, dryness, excessive
tearing, injuries, infections, burns, and gradual loss of vision.
In some embodiments, the eye disorder to be treated is a back of the
eye disease such as diabetic eye disease, symptomatic vitreomacular
adhesion/vitreomacular traction (sVMA/VMT), and wet (neovascular) or dry
AMD (age-related macular degeneration). In some embodiments, the eye
disorder to be treated is one or more retinal and choroidal vascular diseases
(e.g., AMD, retinopathy of prematurity, diabetic macular edema, retinal vein
occlusion, retinopathy associated with toxicity of chemotherapy e.g., MEK
retinopathy). In preferred embodiments, the eye disorder to be treated is age-
48
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
related macular degeneration (AMD). Age-related macular degeneration
(AMD) is a neurodegenerative, neuroinflammatory disease of the macula,
which is responsible for central vision loss. The pathogenesis of age-related
macular degeneration involves chronic neuroinflammation in the choroid (a
blood vessel layer under the retina), the retinal pigment epithelium (RPE), a
cell layer under the neurosensory retina, Bruch's membrane and the
neurosensory retina, itself.
In other embodiments, the eye disorder to be treated is an
inflammatory disease of the eye, i.e., diseases of the eye associated with
inflammation of the tissues of the eye, including, for example, AMD,
retinitis pigmentosa, optic neuritis, sarcoid, retinal detachment, temporal
arteritis, retinal ischemia, arteriosclerotic retinopathy, hypertensive
retinopathy, retinal artery blockage, retinal vein blockage, diabetic
retinopathy, macular edema, Stargardt disease (also known as Stargardt
macular dystrophy or juvenile macular degeneration), geographic atrophy,
neuromyelitis optica, and also including angiogenic diseases including, for
example, retinal neovascularization and choroidal neovascularization. Other
conditions can also result in inflammation and/or angiogenesis in the eye, for
example, infection, sickle cell disease, hypotension, etc.
Further examples of eye disorders that may be treated include
amoebic keratitis, fungal keratitis, bacterial keratitis, viral keratitis,
onchorcercal keratitis, bacterial keratoconjunctivitis, viral
keratoconjunctivitis, conical dystrophic diseases, Fuchs endothelial
dystrophy, meibomian gland dysfunction, anterior and posterior blepharitis,
conjunctival hyperemia, conjunctival necrosis, cicatrical scaring and
fibrosis,
punctate epithelial keratopathy, filamentary keratitis, conical erosions,
thinning, ulcerations and perforations, Sjogren's syndrome, Stevens-Johnson
syndrome, autoimmune dry eye diseases, environmental dry eye diseases,
conical neovascularization diseases, post-conical transplant rejection
prophylaxis and treatment, autoimmune uveitis, infectious uveitis, anterior
uveitis, posterior uveitis (including toxoplasmosis), pan-uveitis,
inflammatory disease of the vitreous or retina, endophthalmitis prophylaxis
49
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
and treatment, macular edema, macular degeneration, age-related macular
degeneration, proliferative and non-proliferative diabetic retinopathy,
hypertensive retinopathy, an autoimmune disease of the retina, primary and
metastatic intraocular melanoma, other intraocular metastatic tumors, open
angle glaucoma, closed angle glaucoma, pigmentary glaucoma and
combinations thereof. Other disorders include injury, burn, or abrasion of
the cornea, cataracts and age related degeneration of the eye or vision
associated therewith.
The dendrimer complexes can be administered in combination with
one or more additional therapeutically active agents, which are known to be
capable of treating conditions or diseases discussed above.
The present invention will be further understood by reference to the
following non-limiting examples.
EXAMPLES
Example 1: Targeted Sustained Intracellular Delivery to Choroidal
Neovascular Lesions After a Single Systemic Administration as
Demonstrated by Imaging
Methods
Hydroxyl dendrimers (-14000 Da) were covalently conjugated to 2-3
indocyanine green (ICG) molecules (D-ICG) per dendrimer via non-
cleavable linkages. Hydroxyl dendrimers (-14000 Da) were covalently
conjugated to 2-3 tetramethylrhodamine (TRITC) molecules (D- TRITC) per
dendrimer via non-cleavable linkages.
Two studies were conducted in C57BL/6 mice (n=5/group)
administered intravenously 100 uL of D-ICG or vehicle control. In the first
study, mice were administered D-ICG or vehicle control at 1, 3, 7, or 14 days
post-laser and eyes were analyzed by optical coherence tomography (OCT)
with ICG imaging at 4 or 24 hr post-dose. Flat-mounts of the sclera-
choroid/retinal pigment epithelial (RPE) complexes were stained by
fluorescently tagged isolectin and IBA-1.
The second study evaluated the localization and persistence of
dendrimer conjugates in the CNV lesion. In the second study, mice were
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
administered intravenously 100 L of D-ICG and 100 pL of D-TRITC (1 hr
after D-ICG) or vehicle control at 24 hr post-laser. Mice analyzed and
sacrificed at 4, 7, 14, 21, and 28 days post-dose (n=5/group). For control
group, free ICG (1.23 mg/mL), 100 pL, IV dosed 24 hr post-laser and mice
analyzed and sacrificed at 2, 4, 7, and 14 days post-dose (n=5/group). Eyes
analyzed by optical coherence tomography (OCT) with ICG imaging. Flat-
mounts of the sclera-choroid/retinal pigment epithelial (RPE) complexes
were stained by fluorescently tagged IBA-1 alone.
Results
No significant release of ICG or TRITC was observed from
dendrimers under in vitro release when was evaluated at 37 C in PBS, pH
7.4 or citrate buffer, pH 5.5 with esterase.
The ability of hydroxyl dendrimers labelled with indocyanine green
(ICG) was evaluated to target choroidal neovascular (CNV) lesions, and
further into macrophages and the retinal pigment epithelium, after systemic
administration in a mouse model of laser-induced CNV.
Systemically administered D-ICG was selectively taken up by cells
within the CNV lesions within 24 hr after dosing, whereas the free ICG
distributes non-specifically and is typically cleared within hours. Reactive
macrophage and microglia endocytosed dendrimer conjugates 24 hr post-
laser and lesion showed greater uptake during early stage of CNV, consistent
with efficacy studies (24 hr post-laser). Dendrimer conjugates localized in
macrophages in CNV lesions as shown by co-localization with IBA-1
positive cells (data not shown). Free ICG control groups showed that free
ICG no longer present in the lesions between 7-14 days post-laser. IBA-1
signal increased up to 24-48 hr after laser injury and isolectin increases
slightly later at the 48h post-laser (FIGs. 1A and 2B). A single systemic D-
ICG dose given 24 hr after laser injury localized to the CNV lesion and
significant D-ICG was still present at the last time point, i.e., 28 days
(FIG.2C).
Hydroxyl dendrimers co-localized with reactive macrophages in
choroids, microglia/macrophages in retina, and RPE cells at the site of
51
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
inflammation/neovascularization. D-ICG and D-TRITC appeared to be
intracellular and focused in regions of IBA-1 signal consistent with previous
studies demonstrating hydroxyl dendrimer uptake in reactive microglia,
macrophage, and RPE cells.
Hydroxyl dendrimers (D-ICG) selectively target to CNV lesions after
systemic administration and persist for at least 28 days post-dose, despite
the
hydroxyl dendrimers are systemically cleared within 48 hr. Thus, the
hydroxyl dendrimer provided a prolonged localization at the CNV lesions
suitable for sustained and targeted therapies, for example, once per month
systemic (subcutaneous or oral) treatment for retinal diseases with minimal
systemic exposure.
Example 2: Suppression of Murine Choroidal Neovascularization After
Systemic Administration of a Targeted Anti-VEGF Therapy
Methods
Hydroxyl dendrimers (-14000 Da), which selectively target
inflammation, were covalently conjugated to analogs of sunitinib, an FDA-
approved potent VEGF receptor tyrosine kinase inhibitor. Conjugates were
made with a cleavable sunitinib analog (D-CSA, compound 6 in FIG.1A) or
a non-cleavable sunitinib analog (D-NSA, compound 3 in FIG.1B) and drug
release was evaluated at 37 C in PBS, pH 7.4 or citrate buffer, pH 5.5 with
esterase. Laser-induced rupture of Bruch's membrane was performed in
both eyes of C57BL/6 mice (n=8/group) 24 hr prior to dose administration.
Mice were administered intravenously (IV, 100 L) vehicle, D-CSA (5.25
(low) or 26.25 (high) mg/kg sunitinib equivalent), D-NSA (6.3 (low) or
15.75 (high) mg/kg sunitinib equivalent), or free sunitinib (32.5 mg/kg). As
a positive control group, a cohort of mice were administered aflibercept
(EYLEACI) intravitreally (IVT; 1 uL, 40 ig). The CNV area was measured
7 days after laser treatment by both fluorescein angiography and flat-mounts
of the sclera-choroid/RPE complexes stained with isolectin IB4.
52
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Results
The efficacy of hydroxyl dendrimers covalently conjugated with
analogs of sunitinib was evaluated in a mouse model of laser-induced
choroidal neovascularization (CNV).
D-CSA was prepared with 5 sunitinib analogs per dendrimer (10.5%
w/w) and D-NSA was prepared with 7 sunitinib analogs per dendrimer
(12.6% w/w). Over 6 days in vitro, D-CSA released ¨65% of the sunitinib at
pH 5.5 with esterase (intracellular conditions) and ¨15% release of sunitinib
occurred over 24 hr at pH 7.4 (plasma conditions). Release of the sunitinib
analog from D-NSA conjugate is minimal.
Statistically significant reductions in the CNV area were observed for
IVT aflibercept and both IV dose levels of D-CSA and D-NSA but not free
sunitinib (even at 5-fold higher doses compared to low dose D-CSA),
compared with vehicle control (FIG.3).
Binding affinity (Kd) to VEGFR2 was assessed with free sunitinib
malate (0.13 nM), sunitinib analog attached via a non-cleavable PEG linker
(1M) and D-NSA (27 nM). The binding affinity data indicated that high
binding affinity was retained in D-NSA. Thus, it has been demonstrated that
conjugation of a sunitinib analog to hydroxyl dendrimers maintains
nanomolar potency for VEGF RTK.
Single doses of D-CSA/D-NSA administered in laser-induced CNV
mouse model demonstrated efficacy comparable to aflibercept administered
intravitreally. The non-cleavable sunitinib analog efficacy in CNV area
reduction suggests that sunitinib release from the dendrimer may not be
required. Previous studies have shown hydroxyl dendrimers and dendrimer-
drug conjugates are retained in CNV lesions > 28 days and systemically
cleared intact within 24 hr in mice and humans without detectable liver or
other off-target toxicity.
Example 3: Duration of Efficacy and Drug Systemic Clearance
Methods
Conjugates were made with a cleavable sunitinib analog (D-CSA,
compound 6 in FIG.1A) or a non-cleavable sunitinib analog (D-NSA,
53
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
compound 3 in FIG.1B). Laser-induced rupture of Bruch's membrane was
performed in both eyes of C57BL/6 mice (n=8/group) 24 hr prior to dose
administration. Mice were administered a single intraperitoneal injection
(IP, 100 L) vehicle, D-CSA (5.25 mg/kg sunitinib equivalent), D-NSA (6.3
mg/kg sunitinib equivalent), or free sunitinib (6.5 mg/kg). As a positive
control group, a cohort of mice were administered aflibercept (EYLEACI)
intravitreally (IVT; 1 uL, 40 ig). The CNV area was measured 7 days and
14 days after laser treatment by both fluorescein angiography and flat-
mounts of the sclera-choroid/RPE complexes stained with isolectin IB4. For
plasma pharmacokinetics study, the same dendrimer labeled with Cy5
administered via a single IP injection was monitored by plasma collection up
to 72 hours after IP administration.
Results
The therapeutic duration and clearance of hydroxyl dendrimers
covalently conjugated with analogs of sunitinib was evaluated in a mouse
model of laser-induced choroidal neovascularization (CNV).
Dendrimer conjugated sunitinib analog, D-CSA and D-NSA,
demonstrated a durable response from a single IP dose with a reduction in
the CNV area at day 7 post-treatment and a further reductions in the CNV
area at day 14 post-treatment. Significant reduction in the CNV area was
observed for IVT aflibercept at day 7 post-treatment but the reduction was
not sustained at day 14 post-treatment (FIG.4A).
In the serum, both D-CSA and D-NSA were cleared within 2 days
post-treatment (FIG.4B). Thus, the dendrimer conjugated sunitinib analog D-
CSA and D-NSA provided a prolonged local effect on CNV lesions with the
lesion size continued to decrease at day 14 post-treatment.
Example 4: Synthesis and Characterization of N, N-Didesethyl Sunitinib
Amide Azide
The design and synthesis of dendrimer-didesethyl sunitinib conjugate
is described in Examples 4 and 5. Overexpression of vascular endothelial
growth factor (VEGF) has been implicated in a number of diseases
associated with angiogenesis. Sunitinib is a receptor tyrosine kinase
inhibitor
54
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
that blocks VEGF receptors and has excellent antiangiogenic activity and is
approved by the FDA for use in different types of cancers. Didesethyl
sunitinib is an active metabolite of sunitinib. Despite the excellent
therapeutic value of sunitinib and its analogues, their clinical development
is
hampered by the associated toxicity. The dendrimer-didesethyl sunitinib
conjugates aim to overcome the dose related toxicities of sunitinib by
attaching it to a hydroxyl terminated dendrimer. The synthesis scheme is
outline in Figure 5 and a generation 4 PAMAM is used as an exemplary
hydroxyl terminated dendrimer.
Step 1: Synthesis of 5-fluoro-2,3-dihydro-1H-indo1-2-one (compound
2)
To a stirred solution of 5-fluoro-2,3-dihydro-1H-indole-2,3-dione
(6.0 gm, 1.0 eq.) in n-butanol (10V) was added triethyl amine (6.12 mL, 1.2
eq.) and followed by hydrazine hydrate (3.56 mL,2.0 eq.) was added at room
temperature. The resulting solution was stirred for 16 hrs at 100 C. Reaction
progress was monitored by TLC (50 % ethylacetate in Hexanes). Once the
reaction was judged to completion, reaction mass was as such evaporated to
dryness under vacuum at 45 C to obtain dark brown solid. The obtained solid
was quenched with water (20 V) and extracted with ethyl acetate (30V) and
organic layer was given water wash. Organic layer was concentrated to
dryness on rotary evaporator. The crude product was purified by
recrystallization using ethyl acetate to get grey color fluffy solid. (4.0 g,
72
% yield.) The compound 2 shown in FIG. 5 was confirmed by 1H NMR,
liquid chromatography, and mass spectrometry.
Step 2: Synthesis of 51 [(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indo1-3-
ylidenelmethy1}-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (compound 4)
To a stirred solution of 5-fluoro-2,3-dihydro-1H-indo1-2-one
(compound 2) (4.0 gm, 1.0 eq.) and 5-formy1-2,4-dimethy1-1H-pyrrole-3-
carboxylic acid (compound 3) (4.41 gm, 1.0 eq.) in ethanol (10V) was added
pyrrolidine (4.42 mL,2.0 eq.) at room temperature. The resulting solution
was stirred for 3 hrs at 80 C. Reaction progress was monitored by TLC (10
% Methanol in DCM). Once the reaction was judged to completion, reaction
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
mass was cooled to room temperature added 2M HC1 solution to pH=3. A
brownish-red precipitate was formed and filtered. The obtained solid was
washed with ethanol (20 V) followed by hexanes (30 V) and filtered to get
reddish-orange solid. (6.6 g, 82 % yield.) The compound 4 shown in FIG. 5
was confirmed by 41 NMR.
Step 3: Synthesis of tert-butyl N12-[(5-[[(3Z)-5-fluoro-2-oxo-2,3-
dihydro-]H-indo1-3-ylidenelmethy1}-2,4-dimethyl-1H-pyrrol-3-
yl)formamidolethylicarbamate (compound 6)
To a solution of 5-11(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indo1-3-
ylidenelmethy11-2,4-dimethy1-1H-pyrrole-3-carboxylic acid (compound 4)
(6.5 g, 1.0 eq.) in DMF were added triethyl amine (6.08 mL, 2.0 eq.)
EDC.HC1 ((8.68 g, 2.1 eq.), HOBT (3.94 g, 1.35 eq.) and tert-butyl N-(2-
aminoethyl) carbamate (4.16 g, 1.2 eq.) and at 0 C. Reaction was stirred at
room temperature for 16 hrs. Reaction mixture was diluted with water (20.0
V), stirred for 10 mm. to precipitate and filtered to get brown solid. The
obtained solid was washed with ethyl acetate (15.0 V), followed by hexanes
(15.0V), filtered and dried to get brownish-orange solid as a tert-butyl N-12-
1(5-11(3Z)-5 -fluoro-2-oxo-2,3-dihydro-1H-indo1-3-ylidenel methyll-2,4-
dimethy1-1H-pyrrol-3-yllformamidolethylIcarbamate (compound 6) (7.5 g,
78 %yield). The compound 6 shown in FIG. 5 was confirmed by 41 NMR.
Step 4: Synthesis of N-(2-aminoethyl)-51 [(3Z)-5-fluoro-2-oxo-2,3-
dihydro-1H-indo1-3-ylidenelmethy1}-2,4-dimethyl-1H-pyrrole-3-
carboxamide (compound 7):
To a solution of tert-butyl N-12-1(5-11(3Z)-5-fluoro-2-oxo-2,3-
dihydro-1H-indo1-3-ylidenelmethy11-2,4-dimethyl-1H-pyrrol-3-
yl)formamidolethyl 1 carbamate (compound 6) (9.0 g, 1.0 eq.) in DCM (10.0
V) was added trifluoro acetic acid (3.0 V) at 0-5 C. Reaction was stirred at
room temperature for 12 hrs. Reaction mass was as such evaporated to
dryness under vacuum at 45 C to obtain dark brown solid. The obtained solid
was washed with diethyl ether (15.0 V) filtered and dried to get orange-
yellow solid (6.0 g crude). The compound 7 shown in FIG. 5 was confirmed
by 41 NMR, liquid chromatography, and mass spectrometry.
56
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Step 5: Synthesis of N121(5-11(3Z)-5-fluoro-2-oxo-2,3-dihydro-M-
indol-3-ylidenelmethyl}-2,4-dimethyl-1H-pyrrol-3-yl)formamidolethy1}-3-
[2-(2-propoxyethoxy)ethoxy]propanamide (compound 9):
To a solution of 342-(2-propoxyethoxy)ethoxylpropanoic acid (8)
(5.95 g, 1.0 eq.) in DMF (10.0 V) were added DIPEA (8.40 mL, 2.0 eq.)
EDC.HC1 (6.90 g, 1.5 eq.), HOBT (0.65 g, 0.2 eq.), N-(2-aminoethyl)-5-
{ R3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indo1-3-ylidenelmethyl}-2,4-
dimethyl-1H-pyrrole-3-carboxamide (compound 7) (11.0 g, 1.0 eq.) and
DMAP (0.294 g , 0.1 eq.) at 0-5 C. Reaction was stirred at room temperature
for 3 hrs. Reaction progress was monitored by TLC (10 % Me0H in DCM).
Reaction mixture was diluted with water (20.0 V) stirred for 10 mm. to form
brown precipitate and filtered. The obtained solid purified by reverse phase
column chromatography to obtain N, N-didesethyl sunitinib amide azide as
an orange solid (5.2 g, 37 % yield). The compound 9 was confirmed by 1H
NMR, liquid chromatography, and mass spectrometry.
Example 5: Synthesis and Characterization of Dendrimer-Didesethyl
Sunitinib Conjugate (D-4517)
Methods
Synthesis and characterization of intermediates and dendrimer
conjugate:
Synthesis of dendrimer hexyne (Compound 2 of FIG. 6A):
Took a dried round bottom flask (250mL) and recorded its empty
weight. Poured the desired amount of the methanolic solution of G4-0H in
the round bottom and evaporated at 60 C for 2 hours. Shifted the flask on the
high vacuum assembly for 1 hour. Recorded the amount of G4-0H in the
flask. Once the weight of G4-0H was recorded, added 50-60 mL of
anhydrous DMF to the flask and evaporated under reduced pressure to
remove any trace of methanol present in the dendrimer which could impact
the efficiency of Steglich esterification. After the evaporation of DMF, the
flask was brought under nitrogen environment. Added anhydrous DMF
(10mL/gram) to the flask and shifted the solution on sonication bath and
sonicated the reaction mixture until clear solution was achieved. 5-Hexynoic
57
CA 03163892 2022-06-03
WO 2021/113662 PCT/US2020/063347
acid was dissolved in 2 ml of DMF and added to the stirring solution. After
minutes, EDC.HC1 and DMAP were added to the stirring solution and the
solution was left on stirring at room temperature for 48 hours. On
completion, DMF dialysis was started in lkDa molecular weight cut-off
5 dialysis bag. DMF dialysis was performed for 8h, replacing DMF once.
After
8h, 30mL of D.I. water was added to the solution in the bag and was dialysed
against water for overnight. The reaction mixture was diluted with HPLC
water and the final volume was made 300-350mL. T1-1- was performed in D.I
water using 3kDa TFF cartridge. The TFF cycle was performed 6-7 times
10 and the final retentate volume was around 100mL which was lyophilized to
obtained sticky solid. The product yield was around 5.5g (74%). The 1H
NMR was recorded at 500MHz instrument in deuterated DMSO where ¨10
mg of compound was used for sample preparation. The loading of hexynoic
acid was calculated by proton integration method. The internal amide peak of
dendrimer between 68.11 ¨ 7.70 ppm was the reference peak. The peak at
64.0ppm corresponding to ester linked protons and peak at 61.6ppm is the
CH2 from hexynoic acid. Proton integration method suggested the
attachment of 9-10 molecules of hexynoic acid per dendrimer. The HPLC
purity was >99%.
Table 1. Reagents for Synthesis of dendrimer hexyne (Compound 2 of
FIG. 6A)
G4-OH 5-Hexynoic EDC.HC1 DMAP
acid
M.W 14279 112.13 191.7 122.17
Amount 10.5g 1.15g 3.52g 1.79g
Millimoles: 0.73 10.3 18.4 14.7
Equivalents 1 14 25 20
Synthesis of dendrimer-didesethyl sunitinib conjugate (compound 3
in FIG. 6B):
Placed dendrimer hexyne (compound 2 of FIG. 6A) in the 250mL
round bottom flask. Dissolved the compound in 40mL anhydrous DMF by
58
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
sonication. The sunitinib-azide solution was added in the reaction mixture by
dissolving it in 20mL DMF and solution was stirred. It was followed by the
addition of 10mL of water to the reaction mixture to stop the precipitation of
copper salt in reaction mixture. After 10 minutes of stirring, copper sulfate
pentahydrate (dissolved in 3mL of water) was added dropwise to the reaction
flask. The stirring solution turned blue in color. After 5 minutes, sodium
ascorbate (dissolved in 3mL of water) was added dropwise to the reaction
mixture and the reaction vial was shifted over oil bath which was set at 40 C.
The reaction mixture was stirred and heated for 24h. On completion, the
DMF was evaporated and the reaction mixture was diluted with 300mL of
10% DMAc in water. To this solution, EDTA (500microliter, 0.5M) solution
was added for copper salt removal by chelation. TFF was performed on the
reaction mixture in water using 3kDa TFF cartridge. 8-10 Diavolumes were
performed in 10%DMAc in water, followed by 5-6 cycles in water as buffer
to remove the solvent traces. The final retentate volume was around 150 mL
which was lyophilized to obtain off yellow solid. The product yield was
5.5g. The 11-1 NMR was recorded at 500MHz instrument in deuterated
DMSO and deuterated water and around 10mg of compound was used for
sample preparation. 100 scans were made for the 11-1 NMR. The 11-1 NMR
indicated the formation of product and 6-7 arms of sunitinib molecule were
attached (Fig. 4). The drug loading is calculated by proton integration
method where peaks corresponding to dendrimer and drug are compared.
The CH2 peak at 1.8ppm corresponding to hexynoic acid and ester linked
CH2 at 4.0ppm is locked as the reference peak from dendrimer side. After the
triazole formation, the new peak in 1H NMR corresponding to CH2 peak
protons next to triazole ring at 6 4.4ppm, 2 aromatic protons from sunitinib
in between 6.92-6.80ppm and 2 NH protons at 10.9 and 13.6ppm were used
to calculate the loading of drug molecules. After the click reaction, there is
formation of 1-4 triazole and the signature proton peak corresponding to
triazole appears in between 6 7.5-8.0ppm which is suppressed by the
presence of internal amide protons. For confirmation of sunitinib attachment,
the 11-1 NMR was recorded in D20 where the disappearance of internal amide
59
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
peaks and presence of triazole peak at 6 7.7ppm were observed. The HPLC
purity was >99%.
Table 2. Reagents for Synthesis of Dendrimer-didesethyl Sunitinib
Conjugate (D-4517)
Compound 2 Desethyl CuSO4.5H20 Na
sunitinib- ascorbate
azide
M.W ¨15000 571.6 249.69 168mg
Amount 5.1g 1.65g 170mg 250mg
Millimoles: 0.340 2.89 0.68 0.85
Equivalents 1 8.5 2 2.5
Protocol for the in vitro kinase binding assay
Kinase-tagged T7 phage strains were prepared in an E. coli host
derived from the BL21 strain. E. coli were grown to log-phase and infected
with T7 phage and incubated with shaking at 32 C until lysis. The lysates
were centrifuged and filtered to remove cell debris. The remaining kinases
were produced in HEK-293 cells and subsequently tagged with DNA for
qPCR detection. Streptavidin-coated magnetic beads were treated with
biotinylated small molecule ligands for 30 minutes at room temperature to
generate affinity resins for kinase assays. The liganded beads were blocked
with excess biotin and washed with blocking buffer (SEABLOCK (Pierce),
1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to
reduce non-specific binding. Binding reactions were assembled by
combining kinases, liganded affinity beads, and test compounds in lx
binding buffer (20% SEABLOCK , 0.17x PBS, 0.05% Tween 20, 6 mM
DTT). Test compounds were prepared as 111X stocks in 100% DMSO. Kds
were determined using an 11-point 3-fold compound dilution series with
three DMSO control points. All compounds for Kd measurements are
distributed by acoustic transfer (non-contact dispensing) in 100% DMSO.
The compounds were then diluted directly into the assays such that the final
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
concentration of DMSO was 0.9%. All reactions performed in polypropylene
384-well plate. Each was a final volume of 0.02 ml. The assay plates were
incubated at room temperature with shaking for 1 hour and the affinity beads
were washed with wash buffer (lx PBS, 0.05% Tween 20). The beads were
then re-suspended in elution buffer (lx PBS, 0.05% Tween 20, 0.5 pM non-
biotinylated affinity ligand) and incubated at room temperature with shaking
for 30 minutes. The kinase concentration in the eluates was measured by
qPCR.
Sample preparation:
Sunitinib malate, sunitinib ester amide linker and D4-sunitinib
conjugate were dissolved in aqueous DMSO to form solution at free drug
(sunitinib) concentration of 10 mM. Each sample solution was further diluted
to 10 M, 3.33 M, 1.11 M, 0.37 M, 0.123 M, 41.2 nM, 13.7 nM, 4.57
nM, 1.52 nM, 0.508 nM and 0.169 nM in DMSO respectively.
Results
Synthesis and characterization:
The synthesis of dendrimer-didesethyl sunitinib analogue is achieved
in 3 steps via copper(I) catalysed alkyne-azide click reaction (FIGs. 6A and
6B). The first step involves the partial modification of the dendrimer surface
hydroxyl groups by attaching a few hexynoic acid linker arms by
esterification to bring alkyne surface groups. Second step is the introduction
of a linker arm on the didesethyl sunitinib with azide terminal. Third step
involves the click reaction of both parts. For the synthesis of dendrimer
hexynoic acid, the as-received ethylenediamine core hydroxyl
polyamidoamine dendrimer (G4-0H, Pharma grade>95% HPLC purity) was
used. Partial esterification of the OH terminated dendrimer (compound 1)
was first performed (Fig. 6A) with 5-hexynoic acid using the EDC.HC1 and
DMAP in anhydrous N, N-dimethylformamide to yield compound 2. 1H
NMR was used for the confirmation of the compound. The loading of the
hexyne linker was calculated by proton integration method by comparing the
linker protons to the internal amide protons of the dendrimer between 68.11
¨ 7.70 ppm. The peak at M.0 ppm corresponding to ester linked protons and
61
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
peak at 61.6 ppm refers the CH2 from hexynoic acid. Proton integration
method suggested the attachment of 8-10 molecules of alkyne linker per
dendrimer. The purity of the construct was evaluated using HPLC and it was
found to be >99%. Linker 342-(2-propoxyethoxy)ethoxylpropanoic acid
was attached to didesethyl sunitinib using EDC.HC1, DMAP, DIPEA, HOBt
in anhydrous DMF to bring azide to participate in click reaction. The drug is
connected through the linker with an amide linkage. The dendrimer hexyne
(2) and didesethyl sunitinib PEG azide were used for performing click
reaction. Copper catalysed click reaction is one of the most efficient
chemical transformation which has brought revolution in the field of drug
discovery and is an excellent tool for conjugation of small or big molecules
to macromolecules, polymers and antibodies. It is known for its easy
execution, milder reaction conditions, compatibility with different functional
groups, regio-selective, enhanced reaction rates, produce cleaner products
with great yields. Copper (II) sulphate pentahydrate and sodium ascorbate
were used for the click reaction in the presence of DMF:H20 (1:1). The
reaction was carried out at room temperature for overnight followed by the
purification by tangential flow filtration. The formation of product (3) was
confirmed by 41 NMR. The 41 NMR spectrum of the conjugate clearly
shows the peaks corresponding to the dendrimer, drug and linkers attached to
it, and the drug loading was calculated by comparing these peaks with the
help of proton integration method. The internal amide protons from the
dendrimer are present in between 6 8.5-7.5 ppm when spectrum is recorded
in deuterated DMSO. These amide peaks are a reference standard for the rest
of the peaks. The ¨NH peaks from drug appear at 6 13.6 and 10.8 ppm.
There are 4 protons from the drug and one triazole proton which is formed
after the click reaction merged with internal amide peaks and comes in
between 6 8.5-7.5 ppm. Additionally, two aromatic protons from sunitinib
situated next to the fluorine group appear at 6 6.95-6.85 ppm. A sharp
triazole peak at 6 7.7 ppm which is a signature peak for the click
transformation is observed when the NMR solvent is switched from
deuterated DMSO to CD30D. After the click, the CH2 present next to the
62
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
azide downshielded and can be observed at 6 4.4 ppm. The comparison of
proton NMR spectra of drug linker, dendrimer intermediate and the final
conjugate was confirmed by 'H NMR. The purity of the dendrimer drug
conjugate, intermediate and drug linker was evaluated using HPLC. The final
conjugate is >99% pure by HPLC. The dendrimer G4-OH and dendrimer
hexyne intermediate is visible at 210 nm channel and the didesethyl suntinib
is visible at 430 nm in HPLC. The retention time of the compound 2 is
around 16.9 minutes but once the hydrophobic drug molecules are attached
to the dendrimer, the peak of the final conjugate shifts towards the right and
comes around 27 minutes which confirms the attachment of hydrophobic
drugs to the dendrimer construct. Once the drug is attached to dendrimer the
peak corresponding to it at both 210 nm (dendrimer absorption wavelength)
and 430 nm (drug absorption wavelength) channels was observed, which
further confirms the formation of product. The drug loading of the dendrimer
conjugate is around 12.6% wt/wt which corresponds to 7 molecules of drug
attached per dendrimer molecule.
Binding affinity:
The kinase comparative binding affinity of D-didesethyl-Sunitinib-
conjugate (Compound D-4517), free sunitinib malate and sunitinib linker
(AVT-4517) was evaluated, and the results are presented in Table 3. The
binding affinity for free sunitinib is 0.13 nM. After the attachment of PEG
linker, the binding affinity decreased around 8 folds to 1.0 nM. The
conjugate exhibited the binding affinity of 27 nM. The results demonstrate
that the conjugation of drug on the dendrimer surface retains the binding
affinity of the drug to RTK domain in nanomolar range. This shows that the
conjugate itself is active and can bind to the receptor without the release of
the drug. It has been shown for the first time that conjugation of a small
molecule inhibitor (300-400 Da) to a large dendrimer (14000 Da) can still
retain nanomolar binding of the small molecule inhibitor.
63
CA 03163892 2022-06-03
WO 2021/113662 PCT/US2020/063347
Table 3: D-didesethyl-Sunitinib-conjugate Kinase (VGEFR2) binding assay
study:
Compounds Structure Gene Kd
Symbol (nM)
Sunitinib H VEGFR2 0.13
N 0
Malate
HN
H
N
0
Sunitinib 0
N3 VEGFR2 1.0
ester amide
H 0
linker
nH
N -
H
(AVT-4517)
D- 0 F VEGFR2 27
(cim )54
N
)6-7
didesethyl- H NH
0
0 N
Sunitinib- D 0
conjugate
(D-4517)
Stability studies in human and rat plasma:
In vitro stability of D-didesethyl sunitinib (D-4517) in human and rat
plasma was further evaluated at physiological conditions. The results
presented in Table 4 suggest that the conjugate D4517 is very stable with 2%
(weight percentage) release in human plasma, and 4% (weight percentage)
release in rat plasma) after 48 h.
64
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
Table 4: In vitro stability study of drug release percentage of D-didesethyl
sunitinib (D-4517) by weight in human and rat plasma at 37 C.
Time point (hours) Release percentage in Release percentage in
human plasma ( %) rat plasma ( %)
0.5 0.13 0.15
1 0.12 0.17
2 0.16 0.31
4 0.2 0.59
6 0.28 0.81
8 0.54 1.42
24 0.76 1.97
48 2.01 3.98
In vitro drug release study:
In vitro drug release study was carried out at pH 7.4 and pH 5.5 with
esterases at 37 C mimicking plasma and intracellular conditions respectively.
The release study was carried out in duplicates. The results are presented in
Figure 7. At intracellular conditions, less than 2 wt% drug arm is being
released in 15 days. At plasma conditions, ¨2% is being released in 24 h and
around ¨4% in 15 days. The ester bond between the dendrimer and the linker
resulted in a loss of the linker with AVT-4517 over time in D-4517. At both
conditions, the conjugate demonstrated good stability.
Example 6: In Vivo Pharmacokinetics of Dendrimer-Didesethyl
Sunitinib Conjugate (D-4517)
D-4517 pharmacokinetics were evaluated in vivo in mice. Female
C57/B16 mice were injected I.P. with 5 or 50 mg/kg D-4517 and blood
samples were collected for determination of plasma D-4517 concentrations.
Peak plasma concentrations were observed at the first time point sampled,
0.5 h. Exposure based on Cmax and AUC was dose related and
approximately dose proportional.
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
The terminal elimination, T1/2, was about 1 hour following both dose levels.
PK parameters estimated by noncompartmental methods are shown in Table
below and mean plasma concentrations versus time are shown in FIG. 8.
5 Table 5: Plasma D-4517 Concentrations Following IP Injection in Mice.
Dose Cmax Tma AUCO-t AUCINF CL/F Vz/F Ti!
mg/k 0.tg/m x (h*ug/m (h*ug/m (mL/h/k (mL/k 2
L) (h) L) L) (h)
5.0 6.86 0.50 7.70 11.7 426 675 1.1
0
5.0 108 0.50 122 130 384 578 1.0
4
Toxicokinetic data was collected in rats. Sprague-Dawley rats
received daily I.P. injections of 12 mg/kg or a single dose of 168 mg/kg D-
4517 or a daily oral dose of 30 mg/kg sunitinib (40.21 mg/kg of sunitinib
malate). Blood samples were collected, and plasma drug concentrations were
determined. Noncompartmental toxicokinetic parameters were estimated.
Figure 9A and 9B show plasma concentration versus time profiles on
Day 1 and Day 14 for the 12 mg/kg D-4517 and sunitinib groups. There did
not appear to be an obvious gender difference in D-4517 plasma
concentrations, but for sunitinib, males had higher concentrations than
females except at the 24 h time point on day 1. D-4517 plasma
concentrations showed a faster decline than sunitinib. Terminal half-lives
could not be reliably estimated because there were not enough time points in
the terminal phase. Sunitinib was measurable 24 hours after dosing but D-
4517 was not measurable beyond 8 hours post-dosing. Consequently, AUC
estimates were higher for sunitinib compared to D-4517. Following a single
dose of 168 mg/kg D4517, plasma concentrations were high at 1 h post
dosing but at the next time point sampled, 24 h, only one animals had a
measurable concentration.
66
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
The pharmacokinetic results indicate that the dose of D-4517 resulted
in comparable maximum concentrations with lower total exposure compared
to sunitinib. Separate rats received sunitinib malate orally for 14 days at a
dose of 40.21 mg/kg. D-4517 was associated with no mortality nor effects
upon clinical observations, body weights, food consumption or clinical
pathology parameters (hematology, clinical chemistry and urinalysis). D-
4517-related gross necropsy findings were limited to yellow discoloration of
adipose tissue and mesentery in males and females at 12 mg/kg and/or 168
mg/kg, which correlated with subacute/chronic inflammation associated with
intraperitoneal administration of test article. Organ weight changes included
statistically significant decreases in spleen weights in males at 168 mg/kg
though this observation had no microscopic correlate. Non-adverse
microscopic findings included of minimal focal pigment in the choroid of the
eyes and subacute/chronic inflammation in the abdominal fat/mesentery in
males and females at 12 mg/kg and 168 mg/kg. Inflammation was likely
secondary to intraperitoneal injection of test article and was observed
secondarily along the serosal surfaces of the stomach, liver, and spleen.
Overall, D-4571 was well tolerated following single or repeated IP
dosing. These observations were in contrast to sunitinib malate which was
associated with various clinical and pathological changes in addition to
mortality in female rats.
Example 7: Single Subcutaneous Dosing Study of Dendrimer-Didesethyl
Sunitinib Conjugate (D-4517)
To evaluate the preferred route of dosing in humans, a single
subcutaneous dosing study of D-4517 was conducted in the laser-induced
CNV mouse model. Control mice (n=8/group) were injected intravitreally
with either vehicle or aflibercept (40 pg) one day after laser treatment.
Three
dose levels of D-4517 (2, 10 and 50 mg/kg; n=8/group) was administered as
a single subcutaneous dose one day after laser treatment. After 14 days, mice
were sacrificed and flat mounts of the sclera-choroid/RPE complexes were
stained with DAPI and isolectin IB4. CNV area was measured with
fluorescent microscopy and imaging software. As shown in FIG. 10, all three
67
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
doses of D-4517 given as a single subcutaneous dose reduced CNV lesion
area significantly. The responses in the D-4517 treated animals were more
consistent than those observed in the aflibercept treated animals. This study
demonstrates significant efficacy observed from subcutaneously
administered D-4517 in CNV models.
Example 8: Conjugation of Didesethyl Sunitinib via A Non-Cleavable
Ether Linkage On Dendrimer
Methods
Synthesis of dendrimer conjugate via a non-cleavable ether linkage
on dendrimer
The synthesis began by the construction of a bifunctional dendrimer.
At dendrimer generation 3.5, 7 alkyne functional groups were introduced
using a polyethyl glycol (PEG) linker with an amine at one end and a hexyne
at the other end to produce a generation 4 bifunctional dendrimer (compound
1 in FIG. 11) with 7 alkyne arms and 57 hydroxyl groups on the surface. The
structure of the dendrimer was confirmed by 1H NMR spectroscopy.
The clickable didesethyl sunitinib analog (compound 2 in FIG. 11,
a.k.a. AVT-4517), including of didesethyl sunitinib, a three ethylene glycol
(PEG3) spacer and a terminal azide, was synthesized to participate in the
click reaction with alkyne groups on the surface of the dendrimer. The active
agent, compound 2, is manufactured using a 5-step synthesis shown in
FIG.5.
AVT-4517 (compound 2 in FIG. 11) is finally reacted with the
bifunctional dendrimer (compound 1 in FIG. 11) with hexyne groups by
copper (I) catalyzed alkyne-azide click chemistry to yield D-4517.2
(compound 3 in FIG. 11) with the full structure shown in FIG. 12. After
conjugation of the analog to the dendrimer, the D-4517.2 is purified by
tangential flow filtration (TFF) to remove any impurities and enable
purification into the final formulation.
68
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
-111-NMR analysis of D-4517.2 conjugates
The formation of product D-4517.2 is confirmed by 1H NMR. The
1H NMR spectrum of the conjugate clearly shows the peaks corresponding
to the dendrimer, drug and linkers attached to it, and the drug loading was
calculated by comparing these peaks with the help of proton integration
method. The internal amide protons from the dendrimer are present in
between 6 8.5-7.5 ppm when spectrum is recorded in deuterated DMSO.
These amide peaks are a reference standard for the rest of the peaks. The ¨
NH peaks from drug appear at 6 13.6 and 10.8 ppm. There are 4 protons
from the drug and one triazole proton which is formed after the click reaction
merged with internal amide peaks and comes in between 6 8.5-7.5 ppm.
Additionally, 2 aromatic protons from sunitinib situated next to the fluorine
group appear at 6 6.95-6.85 ppm. A sharp triazole peak at 6 7.7 ppm which is
a signature peak for the click transformation is observed when the NMR
solvent is switched from deuterated DMSO to CD30D. After the click, the
CH2 present next to the azide down shielded and can be observed at 6 4.4
ppm. NMR is also used to quantitate the number of drug molecules
conjugated to the hydroxyl dendrimer. The drug loading was calculated by
proton integration method by comparing the protons of dendrimer internal
amide protons to drug protons.
HPLC analysis for assessment of purity of D-4517.2
The purity of the dendrimer drug conjugate, intermediate and drug
linker was evaluated using HPLC. The final conjugate is >99% pure by
HPLC. The dendrimer G4-0H and dendrimer hexyne intermediate is visible
at 210 nm channel and the didesethyl suntinib is visible at 430 nm in HPLC.
The retention time of the compound 2 is around 16.9 minutes but once the
hydrophobic drug molecules are attached to the dendrimer, the peak of the
final conjugate shifts
towards the right and comes around 27 minutes, which confirms the
attachment of hydrophobic drugs to the dendrimer construct. Once the drug
is attached to dendrimer the peak corresponding to it can be observed at both
210 nm (dendrimer absorption wavelength) and 430 nm (drug absorption
69
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
wavelength) channels, which further confirms the formation of product. The
drug loading of the dendrimer conjugate is around 12.6% wt/wt which
corresponds to 7 molecules of drug attached per dendrimer molecule.
Size and zeta potential
The size and the zeta potential distribution of the D-4517.2 are
determined using a Zetasizer Nano ZS instrument. For the size measurement,
the sample was prepared by dissolving the dendrimer in deionized water
(18.2 SI) to make a solution with a final concentration of 0.5 mg/mL. The
solution was then filtered through 0.2pm syringe filters (Pall Corporation,
0.2 pm HT Tuffryn membrane) directly into the cell (UV transparent
disposable cuvette, Dimensions: 12.5 x 12.5 x 45mm). For zeta potential
measurement, the sample was prepared at a concentration of 0.2 mg/mL in
10 mM NaCl using above mentioned procedure. Malvern Zetasizer
Nanoseries disposable folded capillary cell was used for the measurements.
The size of D-4517 was 5.5 0.5 nm and zeta potential was slightly positive
(+5.4 0.4 mV).
Size exclusion chromatography multiple-angle laser scattering (SEC-
MALS)
The molar mass of D-4517.2 will be determined by size exclusion
chromatography multipleangle laser scattering (SEC-MALS).
Results
D-4517 has nanomolar affinity for VEGFR2 and does not require the
release of the active drug, AVT-4517. To further increase the stability of the
conjugate under physiological conditions and further reduce the release of
the drug from the conjugate as observed in D-4517 buffer and plasma
stability studies, the cleavable ester linkages on the dendrimer surface were
replaced with non-cleavable linkages as demonstrated in the structure of
D-4517.2 (FIG. 12). There are no cleavable bonds in the structure of D-
4517.2.
D-4517.2 is a covalent conjugate of generation-4, hydroxyl-
terminated PAMAM dendrimers, containing an ethylene diamine (EDA)
core, amidoamine repeating units lCH2CH2CONHCH2CH2N1), and 64
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
hydroxyl end groups (chemical formula: C622Hils4N1860188) with didesethyl
sunitinib analog (AVT-4517) conjugated to the dendrimer by a highly
efficient click chemistry approach. The hydroxyl, generation-4, PAMAM
dendrimers are mono-disperse and produced with high compositional purity
(>95%). For the preparation of D-4517.2, seven of the 64 hydroxyl groups
on the dendrimer are modified to attach AVT-4517 (-12.6% of total mass).
Stability studies in human, mouse and rat plasma
In vitro stability of dendrimer didesethyl sunitinib conjugates, D-
4517 and D-4517.2, in human, mouse and rat plasma was evaluated at
physiological conditions. The results presented in FIG.13. Compared with
D4517 (2% (weight percentage) release in human plasma, and 4% (weight
percentage) release in rat plasma), the plasma stability of D4517.2 is
improved significantly. At 48 hrs, in all three plasma, less than 0.5% drug
(by weight) was released from dendrimer drug conjugates.
Binding affinity
The kinase comparative binding affinity of D-4517 and D-4517.2 was
evaluated, and the results are presented in Table 6.
Table 6. Dendrimer didesethyl sunitinib conjugates, D-4517 and D-4517.2
binding assay study
Gene
Compound Name Symbol Modifier Kd (nM)
D4517 VEGFR2 = 27
D4517 VEGFR1 = 1100
D4517 CSF1R = 82
D4517 KIT = 3.4
D4517 PDGFRA = 16
D4517 PDGFRB = 11
D-4517.2 CSF1R = 41
D-4517.2 VEGFR1 = 890
D-4517.2 KIT = 3
D-4517.2 PDGFRA = 11
D-4517.2 PDGFRB = 7.5
D-4517.2 VEGFR2 = 14
71
CA 03163892 2022-06-03
WO 2021/113662
PCT/US2020/063347
The IC50 results of D-4517.2 is lower than D-4517 on all tested
assay, which indicates the stronger binding between D4517.2 and tyrosine
kinase receptor.
Unless defined otherwise, all technical and scientific terms used
herein have the same meanings as commonly understood by one of skill in
the art to which the disclosed invention belongs. Publications cited herein
and the materials for which they are cited are specifically incorporated by
reference.
Those skilled in the art will recognize, or be able to ascertain using no
more than routine experimentation, many equivalents to the specific
embodiments of the invention described herein. Such equivalents are
intended to be encompassed by the following claims.
72
